Postoperative Lung Injury- The path from Initiation to Clinical Diagnosis:a molecular view on a complex pathophysiological process by Maltesen, Raluca
 
  
 
Aalborg Universitet
Postoperative Lung Injury- The path from Initiation to Clinical Diagnosis
a molecular view on a complex pathophysiological process
Maltesen, Raluca
DOI (link to publication from Publisher):
10.5278/vbn.phd.engsci.00156
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Maltesen, R. (2016). Postoperative Lung Injury- The path from Initiation to Clinical Diagnosis: a molecular view
on a complex pathophysiological process. Aalborg Universitetsforlag. Ph.d.-serien for Det Teknisk-
Naturvidenskabelige Fakultet, Aalborg Universitet https://doi.org/10.5278/vbn.phd.engsci.00156
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 29, 2020
R
A
LU
C
A
 G
. M
A
LTE
S
E
N
P
O
S
TO
P
E
R
ATIV
E
 LU
N
G
 IN
JU
R
Y- TH
E
 PATH
 FR
O
M
 IN
ITIATIO
N
 TO
 C
LIN
IC
A
L D
IA
G
N
O
S
IS
POSTOPERATIVE LUNG INJURY-  
THE PATH FROM INITIATION TO  
CLINICAL DIAGNOSIS
A MOLECULAR VIEW ON A  
COMPLEX PATHOPHYSIOLOGICAL PROCESS
BY
RALUCA G. MALTESEN
DISSERTATION SUBMITTED 2016
 
 
 
 
POSTOPERATIVE LUNG INJURY- 
THE PATH FROM INITIATION TO 
  CLINICAL DIAGNOSIS  
                A MOLECULAR VIEW ON A 
COMPLEX PATHOPHYSIOLOGICAL PROCESS  
by 
Raluca G. Maltesen 
 
PhD dissertation  
June, 2016 
 
. 
  
 
 
    
                                           
PhD Series:    The Faculty of Engineering and Science, Aalborg University 
 
 
 
ISSN: (online): 2246-1248 
ISBN: (online): 978-87-7112-740-9 
 
Aalborg University Press 
Skjernvej 4A, 2nd floor 
DK – 9220 Aalborg Ø 
Phone: +45 99407140 
aauf@forlag.aau.dk 
forlag.aau.dk 
 
© Copyright by author 
Printed in Denmark by Rosendahls, 2016 
Thesis submitted:  30-06-2016 
 
PhD supervisor:  Professor MSO Reinhard Wimmer 
Dep. of Chemistry and Bioscience 
Aalborg University, Denmark 
 
 
Assistant PhD supervisor:  Clinical Professor Bodil Steen Rasmussen 
Dep. of Clinical Medicine 
Aalborg University Hospital, Denmark 
  
 
PhD committee: 
 
 
 
Professor Jeppe Lund Nielsen (chairman)
Aalborg University
Department of Chemistry and Bioscience
 
Professor Tone Frost Bathen
Dept. of Circulation and Medical Imaging
The Norwegian University of Science and Technology (NTNU)
 
Senior Clinical Lecturer Nandor Marczin
Section of Anaesthetics, Pain Medicine and Intensice Care
Department of Surgery and Cancer
Faculty of Medicine
Imperial College London
Harefield Hospital
 
 
PREFACE  
This PhD thesis is submitted in partial fulfilment of the requirements for obtaining 
the degree of Doctor of Philosophy. The work was financially supported by the 
Department of Chemistry and Bioscience, Section of Biotechnology, Faculty of 
Engineering and Science, Aalborg University and the Department of Anaesthesia 
and Intensive Care Medicine, Aalborg University Hospital, Denmark. The 
experimental work was carried out at the NMR Laboratory at the Department of 
Chemistry and Bioscience, with Professor MSO Reinhard Wimmer as the main 
supervisor. 
The dissertation consists of an introduction summarizing literature relevant to the 
project, aims of study, methods, results and discussions, two published papers 
(Study I, II), one manuscript (Study III), and one patent application (Study IV). 
I would like to take this opportunity to express my appreciation to all those persons 
who provided me with invaluable support and assistance. First of all, I would like to 
thank my supervisors, Professor MSO Reinhard Wimmer and Clinical Professor 
Bodil Steen Rasmussen for giving me the opportunity to work in such an interesting 
field. It has been very fascinating and educational to have both a technical and a 
clinical perspective on my research project.  
Special appreciation is also extended to all my co-authors for their helpful 
discussions and contributions to the studies included in this thesis. I greatly 
appreciated the help from my colleague MD MSc Munsoor Ali Hanifa, who has 
introduced me to the world of metabonomics, and has captured my interest within 
big-data analysis. Appreciation also goes to Professor MD Søren R. Kristensen 
from the Department of Clinical Biochemistry for his ideas and suggestions, as well 
as for the excellent comments regarding the molecular interpretation of the data; 
Senior Researcher Shona Pedersen from the Department of Clinical Biochemistry 
for her valuable comments, enthusiasm, and help whenever needed; and Associate 
Professor Sergey Kucheryavskiy from the Department of Chemistry and Bioscience 
for sharing his chemometrics ideas with me.  
Finally, I owe a debt of gratitude to my husband and our children for their 
understanding, support, and patience during the many hours I missed being in their 
company. 
  
 
 
OBJECTIVES 
Respiratory disorders are amongst the most complex and frequently encountered 
diseases in the intensive care unit (ICU). A wealth of clinical and biological 
information is available on patients diagnosed with pulmonary dysfunction after 
cardiac surgery. However, the primary reasons and paths involved in disease 
progression remain largely unknown. The major reason for this deficiency is that 
the disease involves complex mechanisms, including the interaction of different 
cells and molecules. 
Early detection of pulmonary dysfunction is the most effective way to improve 
patients’ outcomes postoperatively. To understand its complexity, new ideas and 
approaches are needed. Metabonomics provides a powerful platform for biomarker 
discovery and for the detection of altered biochemistry, which could help with early 
diagnosis. The main objective of this thesis was to investigate whether metabolome 
analysis could be used to detect early signs of molecular impairments causing 
progression to postoperative lung injury in patients undergoing cardiac surgery with 
the use of cardiopulmonary bypass (CPB). 
During the course of the study it became clear that nothing about this disease was 
straightforward. The main problems being: the multiple perturbed mechanisms 
occurring in parallel or in series; patients’ preclinical histories (e.g. lifestyle, prior 
diseases, etc.); surgical trauma elicited on each individual; and the lack of early 
biomarkers.  
Although my area of research was metabolome analysis, I became involved in the 
investigation of clinical, biochemical, inflammatory, and coagulation data. After 
attending four open-heart surgeries, it became clear that all these platforms must be 
included, to get a more realistic insight into the mechanisms underpinning disease 
progression. Being a part of different laboratories and units (e.g. NMR 
Spectroscopy, Anaesthesia and Intensive Care Unit, and Clinical Biochemistry), has 
given me the opportunity to be involved in investigating disease progression from 
multiple angles. By integrating the engineering and clinical world, we discovered 
some interesting results. We found that the early pathological development of lung 
injury involves alteration in the levels of more than 60 metabolites (Study I, Study 
III, and Study IV), coagulant and fibrinogen factors (Study II), and pro-
inflammatory mediators (manuscript in preparation). Although we have achieved a 
lot, there is still much to learn.  
I have spent the main part of my PhD analysing samples collected on the first 
morning postoperatively (Study I and IV). The main objective with this analysis 
was to investigate whether we could detect early signs of subsequent impairment, 
 
 
and to learn NMR-based metabonomics. The most exciting part was learning how 
to think ‘big-data’ and how to analyse complex information. All aspects, from 
signal processing, the choice of machine learning algorithms, model optimization, 
feature selection, validation, multivariate data analysis, biostatistics, programming, 
and to the visual representation of the data, were important tasks that I am grateful 
to have learn during this PhD. With regards to the biological aspects, I have spent a 
significant amount of time searching for the ‘needle in the haystack’ and looking 
for meaning in the biological information obtained. This involved the identification 
of metabolites and their complex interactions, as well as the identification of 
possible biomarkers and the optimal combination that could achieve the highest 
predictive values. Finding which metabolites were connected to each other and how 
they may be involved in disease progression was an exciting puzzle, and a valuable 
learning process.  
The main objective of analysing the rest of the time series data (Study III), 
involving the analysis of nearly 850 samples collected before, during, and after the 
end of surgery, was to understand how the procedure affected the human 
metabolome, and how the this may elicit the development of lung injury. The main 
achievements from this study were finding how surgery affected metabolites, and 
how the metabolome could predict disease progression while patients were still at 
the operating room. In addition, this study confirmed and validated our findings 
from the earlier study conducted on samples from the first morning postoperatively.  
While I have achieved the main objective of this study, there is still a long way to 
go and many questions to answer. Are the identified mechanisms similar in other 
types of patients undergoing cardiac surgery (e.g. sepsis, chronic obstructive 
pulmonary disease)? Can these results help to find novel therapeutics to attenuate, 
or even prevent, disease progression? Can our approach be used in hospitals? …  
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ENGLISH SUMMARY 
Introduction: Postoperative pulmonary dysfunction after cardiac surgery with the 
use of cardiopulmonary bypass (CPB) is common, ranging from transient 
hypoxemia to severe lung injury. Even after uncomplicated surgeries, some patients 
experience a systemic inflammatory response, a disrupted coagulation, ischemia-
reperfusion lung injury, and oxidative stress. Since the nadir values of partial 
pressure of arterial oxygen (PaO2) appears on the second to third postoperative day, 
it is difficult to predict which patients will develop pulmonary dysfunction. 
Currently, there is no early diagnostic test to detect the progression to hypoxaemia 
and no molecular-driven intervention to prevent its course.  
Hence, we hypothesized that the surgery elicits molecular changes during, or early 
after weaning from CPB, that can be related to the subsequent hypoxaemia.  
Aims: Thus, the aims of this study were to (1) identify possible molecular changes 
(e.g. metabolites, coagulant and fibrinolytic factors) that occur as a consequence of 
cardiac surgery; (2) to relate these changes to the later degree of pulmonary 
dysfunction; and (3) to identify the possible mechanisms that are involved in disease 
progression.  
Methods: Fifty consecutive patients undergoing cardiac surgery with use of CPB 
were included. Nearly 850 blood samples were collected from the systemic and 
pulmonary microcirculation at ten different time points: the day before surgery, 
intraoperatively, and postoperatively for up to three days. Changes in the levels of 
metabolites were analysed by means of nuclear magnetic resonance (NMR) 
spectroscopy and multivariate data analyses such as principal component analysis 
(PCA) and partial least-square regression (PLS) analysis. Changes in the levels of 
coagulant and fibrinolytic markers were assessed by means of ELISA kits assays.  
Results: All patients had normal preoperative PaO2; 11.3±1.3 kPa (mean±SD). 
PaO2 decreased to 7.8±1.4kPa at 72 hours postoperatively. Twenty three patients 
presented moderate hypoxemia (8.4>PaO2≥ 6.3kPa), nine presented severe 
hypoxaemia (PaO2< 6.3kPa), while eighteen patients showed no sign of hypoxaemia 
(PaO2> 8.5kPa) on the third postoperative day.  
There are several significant findings in this present study. Firstly, metabolome 
analysis by PCA revealed immediate and striking changes in both the pulmonary 
and systemic samples as a consequence of cardiac surgery. Secondly, prolonged 
ischemia, and duration of CPB and CABG impacted both the metabolome and the 
coagulant and fibrinolytic activity, especially in patients developing hypoxaemia. 
Thirdly, several metabolite markers of surgical trauma were identified and were 
related to the development of hypoxaemia. Fourthly, the intraoperative metabolome 
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indicated a possible predisposition to lung injury, since PLS regression analysis 
detected a 0.9 cross-validated correlation with PaO2 measured 72 hours post-CPB. 
Finally, a ‘metabolic biosignature’ was identified that clearly discriminated 
unaffected from hypoxaemic patients while patients were still undergoing the 
surgery. The results suggest that patients progressing to hypoxaemia have a limited 
metabolic reserve with regard to adenosine triphosphate (ATP) synthesis, deranged 
antioxidant defence system, excessive activated lipolysis, and more coagulant and 
fibrinolytic activity, which have probably made them more prone to produce an 
exaggerated stress response to the cardiac surgery.  
Conclusion: To the best of our knowledge, this is the first comprehensive study 
demonstrating the link between intra- and postoperative time-dependent molecular 
changes and the later development of postoperative hypoxaemia. The study provides 
novel insights into the underlying mechanisms that trigger progression into 
hypoxemia, allowing for new hypothesis and treatment options to come.  
Further research is needed in this complex research field to confirm the results and 
to achieve even better understanding about the molecular mechanisms leading to 
disease progression.  
 
  
 
 
DANSK RESUME 
Baggrund: Postoperativ lungedysfunktion efter hjertekirurgi med anvendelse af 
kardiopulmonal bypass (CPB) er en almindlig fremkommende tilstand, som spænder 
fra forbigående hypoxæmi til svær lungeskade. Selv efter relativt ukomplicerede 
operationer, oplever nogle patienter en systemisk inflammatorisk respons, en ændret 
koagulationsaktivitet, iskæmi-reperfusion lungeskade, og oxidativt stress. Da de 
laveste værdier af partieltrykket af oxygen i arteriel blod (PaO2) oftest forekommer 
på anden til tredje postoperative dag, er det vanskeligt, at forudsige og udpege de 
patienter som vil udvikle lungedysfunktion. På nuværende tidspunkt findes der 
ingen tidlig diagnostisk test som kan detektere progressionen til hypoxæmi. Desuden 
findes der ingen terapeutisk behandlingsmåde til at forhindre dens progression.   
Vores hypotese har været at operationen fremprovokerer molekylære ændringer i 
kroppen under selve kirurgien eller tidligt herefter, der kan muligvis relateres til den 
efterfølgende hypoxæmi.    
Formålene med denne Ph.d. afhandling var at (1) identificere mulige molekylære 
ændringer i fx metabolitter, koagulant og fibrinolytiske faktorer, der opstår som 
følge af hjertekirurgi; (2) at relatere disse ændringer til senere grad af lunge-
dysfunktion; og (3) at identificere de eventuelle mekanismer, der indgår i sygdoms-
progression.  
Metoder: Halvtreds konsekutive patienter, der gennemgik hjertekirurgi med brug af 
CPB blev medtaget i studiet. Næsten 850 blodprøver blev opsamlet fra den 
systemiske og pulmonale cirkulation på ti forskellige tidspunkter: dagen før 
operationen, intraoperativt og postoperativt i op til tre dage efter CPB. Ændringer i 
metabolitternes koncentration blev analyseret ved hjælp af nuclear magnetic 
resonance (NMR) spektroskopi og multivariat dataanalyser, så som principal 
component analysen (PCA) og partial least-square (PLS) regression analysen. 
Ændringer i koagulant og fibrinolytiske faktorer blev analyseret ved hjælp af ELISA 
kits analyser.  
Resultater: Alle patienter havde normal præoperativ PaO2 (11.3±1.3kPa; 
middelværdi±SD). Tre dage efter operationerne faldt deres PaO2 værdier til 7.8 ± 
1.4kPa. Treogtyve patienter udviklede moderat hypoxæmi (8.4 >PaO2≥ 6.3kPa), ni 
havde svær hypoxæmi (PaO2< 6.3kPa), mens de resterende patienter viste ingen 
tegn på hypoxæmi (PaO2 > 8.5kPa) på tredje postoperative dag. 
PCA analysen viste at den pulmonale og systemiske metabolitprofil ændrede sig 
markant som følge af hjertekirurgi. Derudover fremgik det af resultaterne at 
langvarigt iskemi-, CPB- og CABG-tid påvirkede både metabolomet og den 
koagulant og fibrinolytisk aktivitet, især hos de patienter som udviklede hypoxæmi. 
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Desuden blev der identificeret flere metabolitmarkører for det kirurgiske trauma, og 
nogle af disse blev relateret til udviklingen af hypoxæmi. PLS regressionsanalysen 
har vist en 0.9 korrelation mellem metabolomet ved afsluttet CPB og de målte PaO2 
værdier på den tredje dag efter operation. Endelig blev en ”metabolisk biosignatur” 
identificeret som kunne differentiere patienter der udviklede hypoxæmi af patienter 
som ikke blev påvirket af lungeskade. Denne biosignatur har vist sig at kunne 
forudsige sygdomsudviklingen allerede under operationen. Resultaterne viste også, 
at de patienter som udviklede hypoxæmi, havde en begrænset metabolisk reserve i 
forhold til adenosintrifosfat (ATP) og antioxidantsyntesen, og en højre grad af 
lipolytisk-, koagulant- og fibrinolytisk aktivitet. Dette gjorde dem mere tilbøjelige til 
at producere en forhøjet stressreaktion som følge af hjertekirurgi. 
Konklusion: Dette er den første omfattende undersøgelse der pointerer 
sammenhængene mellem molekylære intra- og postoperative tidsafhængige 
ændringer, som kan føre til senere udvikling af postoperativ hypoxæmi. 
Undersøgelsen giver nye indsigter i de underliggende mekanismer, som muligvis 
udløser progression i hypoxæmi, og giver mulighed for nye hypoteser og 
behandlingsmuligheder fremover. 
Der er brug for yderligere undersøgelser indenfor dette komplekse forsknings-
område for at bekræfte resultaterne og for at opnå endnu bedre forståelse for de 
molekylære mekanismer, som kan føre til udvikling postoperative lungeskade.  
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS  
ALI acute lung injury 
ANOVA analysis of variance 
ARDS acute respiratory distress syndrome 
ATP adenosine triphosphate 
BCAA 
BALF 
branched-chain amino acids 
bronchoalveolar lavage fluid 
CABG coronary artery bypass grafting 
CPMG Carr-Purcell-Meiboom-Gill 
CPB cardiopulmonary bypass 
CV cross-validation 
DAG diacylglyceride 
DAGPL diacylglycerophospholipid 
FA fatty acid 
FID  free induction decay 
FiO2 fraction of oxygen inspired 
F12 fragment 1.2 
GPC glycerophosphocholine 
1H NMR proton nuclear magnetic resonance 
HMDB human metabolome database 
HSQC hetero-nuclear single quantum coherence 
ICU intensive care unit 
IL interleukin 
LA left atrium 
LV latent variables 
MUFA monounsaturated fatty acid 
N-Ac-Gal n-acetyl-galactosamine 
N-Ac-Glc n-acetylglucosamine 
PA pulmonary artery 
PaO2 partial pressure of oxygen 
PAP plasmin-antiplasmin 
PC phosphatidylcholine 
PC1, PC2 principal component 1 and 2 
PCA principal component analysis 
PEP phosphoenoyl pyruvate 
PLS partial least squares 
PLS-DA partial least squares-discriminant analysis 
ppm parts per million 
PUFA polyunsaturated fatty acid 
RF radiofrequency 
ROC receiver operating characteristic 
ROS reactive oxygen species 
SD       standard deviation 
SM sphingomyelin 
TCA  tricarboxylic acid 
TOCSY total correlation spectroscopy 
1D, 2D one- and two-dimensions 
3-HBA 3- hydroxibutyric acid 
POSTOPERATIVE LUNG INJURY- THE PATH FROM INITIATION TO CLINICAL DIAGNOSIS 
 
    
 
 
TABLE OF CONTENTS 
Chapter 1. BACKGROUND ............................................................................................... 1 
1.1. Coronary artery disease ................................................................................... 1 
1.1.1. CABG-surgery ......................................................................................... 2 
1.2. Postoperative pulmonary dysfunction ............................................................. 3 
1.2.1. Gas exchange ........................................................................................... 3 
1.2.2. Risk factors for pulmonary dysfunction ................................................... 6 
1.2.3. Molecular mechanisms of pulmonary dysfunction .................................. 7 
1.2.4. Detection of pulmonary dysfunction ........................................................ 9 
1.2.5. Biomarkers of pulmonary dysfunction ..................................................... 9 
Chapter 2. AIMS OF STUDY ........................................................................................... 11 
2.1. Preventing pulmonary dysfunction ............................................................... 11 
2.1.1. Study design and research questions ...................................................... 11 
2.1.2. Possible outcomes .................................................................................. 11 
2.1.3. Methodology .......................................................................................... 12 
Chapter 3. METABONOMICS ........................................................................................ 13 
3.1. Metabolites .................................................................................................... 13 
3.1.1. The human metabolome ......................................................................... 14 
3.2. Metabolome analysis ..................................................................................... 15 
3.2.1. Analytical techniques ............................................................................. 15 
3.2.2. Approaches for data analysis.................................................................. 17 
3.2.3. Metabonomics in acute lung diseases .................................................... 19 
Chapter 4. METHODOLOGY, MATERIALS, AND METHODS ................................ 21 
4.1. Methodology ................................................................................................. 21 
4.1.1. Study population .................................................................................... 21 
4.1.2. Outcomes ............................................................................................... 22 
4.1.3. Chronology of the studies ...................................................................... 22 
4.2. NMR-based metabonomics sample preparation ............................................ 23 
4.2.1. Sample variation..................................................................................... 23 
4.2.2. Sample preparation................................................................................. 24 
POSTOPERATIVE LUNG INJURY- THE PATH FROM INITIATION TO CLINICAL DIAGNOSIS 
 
4.3. Data acquisition by NMR .............................................................................. 24 
4.3.1. The principles of an NMR experiment ................................................... 25 
4.4. Data processing ............................................................................................. 28 
4.4.1. Spectra pre-processing ........................................................................... 28 
4.4.2. Spectra post-processing .......................................................................... 28 
4.5. Data analysis ................................................................................................. 29 
4.5.1. Principal Component Analysis ............................................................... 31 
4.5.2. Partial Least Square Regression and Discriminant Analysis .................. 31 
4.5.3. Other statistical analyses ........................................................................ 32 
4.6. Data visualization .......................................................................................... 32 
Chapter 5. RESULTS AND DISCUSSIONS ................................................................... 34 
5.1. Study I and Study III ..................................................................................... 34 
5.2. Study II .......................................................................................................... 52 
Chapter 6. CONCLUSIONS ............................................................................................. 55 
Chapter 7. PERSPECTIVES AND FUTURE DIRECTIONS ....................................... 57 
Literature list ...................................................................................................................... 59 
Appendices (Papers, patent, and additional results) ......................................................... 1 
 
  
 
 
TABLE OF FIGURES 
Figure 1-1  Vein and artery bypass grafts __________________________________ 2 
Figure 1-2  The gas exchange across alveoli ________________________________ 4 
Figure 1-3  The haemoglobin oxygen dissociation curve ______________________ 5 
Table 3-1: A comparison of the NMR and MS techniques ____________________ 17 
Table 4-1 Patient characteristics ________________________________________ 21 
Figure 4-2 Approaches to analyse metabonomics data ______________________ 30 
Figure 5-1 Workflow scheme for Study I and Study III _______________________ 35 
Figure 5-2 Partial pressure of oxygen (PaO2) ______________________________ 36 
Figure 5-3 The metabolite ‘journal’ of patient no. 12 _______________________ 36 
Figure 5-4 Metabolome changes as a consequence of surgery ________________ 38 
Figure 5-5 Time-dependent metabolic changes ____________________________ 39 
Table 5-1 Metabolite changes over time in LA and PA samples _______________ 40 
Figure 5-6 Metabolome screening reveals predisposition to hypoxaemia _______ 42 
Figure 5-7 The effects of prolonged surgical procedure ______________________ 44 
Table 5-2 The chronological metabolic events  ____________________________ 45 
Figure 5-8 Metabolites showing time- and phenotype dependent changes ______ 46 
Figure 5-9 A time course comparison of coagulation and fibrinolytic activity ____ 53 
Figure 7-1 The progression of postoperative lung injury from 'healthy' state _____ 58 
Table C1 Clinical and procedural characteristics of the study population ______ C-39 
Figure C1 Metabotyping patients’ journeys _____________________________ C-40 
Table C2 Metabolite changes as a consequence of CPB ____________________ C-41 
Figure C3 Patients’ metabolic journeys _________________________________ C-44 
Figure C4 Early predispositions to lung injury defined by hypoxaemia ________ C-44 
Figure C5 Metabolic signature of lung injury ____________________________ C-47 
Figure C-S1 Partial pressure of oxygen _________________________________ C-48 
Table C-S1 Prolonged surgical procedure affects the metabolome ___________ C-48 
Figure C-S2 Plasma metabolic profiles _________________________________ C-49 
Table C-S2 Early prediction of hypoxaemia______________________________ C-50 
Figure E1: Fitting accuracy assessment ________________________________ E-72 
Figure E2: Within and bewteen days reproducibility  ______________________ E-72 
 
 
 
1 
CHAPTER 1. BACKGROUND  
Cardiovascular disease is society's number one health problem (1), being the leading 
cause of death in many countries (2, 3). The vast majority of these patients suffer 
from coronary heart disease (2). Nearly one million patients undergo coronary artery 
bypass grafting (CABG) surgery with the use of cardiopulmonary bypass (CPB) 
each year (4), of which more than 2000 procedures are performed in Denmark (5). 
Patients undergoing cardiac surgery are at risk of developing postoperative 
pulmonary dysfunction (6). Pulmonary dysfunction has been known since the 
earliest days of cardiac surgery (7-10), yet, predicting which patients will develop 
postoperative complications is difficult. Several risk factors are known to influence 
the development of postoperative pulmonary dysfunction, including previous 
cardiac surgery (11), the surgical procedure itself (6), blood transfusion (11, 12), 
anaesthesia, and the use of CPB (8, 13, 14). In addition, polymorphisms in the genes 
encoding some inflammatory mediators (15, 16),
 
and increased circulating free fatty 
acids (17) have recently been identified as predictors of early pulmonary 
dysfunction after surgery. While these factors are crucial for the early 
prognostication of at-risk patients, there is still need for more research-based 
knowledge to gain a better understanding of the molecular reasons as to why certain 
patients develop life-threatening complications postoperatively, while others do not.  
This PhD thesis will focus on investigating the intra- and early postoperative 
molecular changes occurring in patients undergoing CABG, and on identifying 
possible associations with the progression to pulmonary dysfunction. Small 
molecules (or metabolites) are the end products of genes, transcripts, and protein 
regulation. Since they are strongly influenced by environmental changes (e.g. 
disease progression, medication) (18), measuring metabolic variations in response to 
CABG could potential reveal an individual’s risk of developing pulmonary 
dysfunction. The metabolite studies presented in this thesis will serve as an example 
of an approach to identify molecular perturbations and predictive markers of the 
degree of the dysfunction. In addition, one study based on coagulation and 
fibrinolysis factors will serve as a small example of macromolecular changes 
occurring in some patients early postoperatively. The findings of the individual 
studies will contribute to the pool of knowledge upon which future research and 
possible new treatment options may be based.  
1.1. CORONARY ARTERY DISEASE  
More than 17 million Americans suffer from cardiovascular diseases, of which, 
approximately 11 million suffer from coronary artery disease (CAD) (19). CAD is 
caused by the build-up of cholesterol deposits in the wall of coronary arteries 
supplying the heart muscle. Accumulation of cholesterol limits the blood flow to the 
heart and causes poor blood supply (or ischemia), chest pain, and even heart attack. 
Treatments of CAD include changes in lifestyle (diet, exercise, weight loss, and 
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smoking cessation), medication to lower cholesterol levels, and surgery for patients 
with more severe symptoms. Surgical treatments may involve dilatation of the 
coronary artery with a balloon (percutanaeous cardiac intervention), or CABG 
performed with, or without, the use of CPB. (20)  
Since this thesis is based upon patients undergoing CABG, only this subject will be 
discussed in the following section.    
1.1.1. CABG-SURGERY  
CABG is an open-heart surgery. During the procedure new arteries are created to 
improve blood supply to the heart (21) (Figure 1-1).  
 
Figure 1-1  Vein and artery bypass grafts are attached to the heart. During CABG, 
a healthy artery from the forearm, or vein from the leg is grafted (or connected) to 
the heart and blood bypasses (or goes around) the blocked portion of the coronary 
artery, creating a new path for oxygen-rich blood to flow to the heart muscle. 
(Copyright © 2016 Icahn School of Medicine at Mount Sinai)   
CABG is performed under anaesthesia. During anaesthesia a tube is inserted through 
the mouth to help patients breathing during and following hours postoperatively 
(20). After the induction of anaesthesia, an incision in the middle of the sternum (or 
sternotomy) is required, and the CABG is then performed either on a beating (off-
pump) or a stopped heart (on-pump or CPB). About 80% of all CABG surgeries are 
performed on-pump (22). During on-pump CABG the pulmonary ventilation is 
stopped and the lungs are collapsed to ensure stabilization of the heart. 
Subsequently, the CPB takes over the functions of the heart and lungs, allowing for 
proper blood oxygenation and oxygen delivery during the surgical procedure. (23) 
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Postoperatively, patients are admitted to intensive care units (ICUs) for 1-2 days, 
where their breathing is facilitated by a mechanical ventilator. At the ICUs 
additional blood transfusions, medications, and drainage of the excessive fluids 
gained during surgery is often necessary. (20) Patients are usually discharged from 
the hospital within a week after surgery. However, in some cases, complications 
may occur (22). Among the most common complications are irregular heartbeat, 
stroke, infection of the sternum (20), pulmonary dysfunction (6, 8, 12, 14, 24-28), 
and acute renal failure (21).  
Since this thesis is based on postoperative pulmonary dysfunction, only this topic 
will be discussed further. 
1.2. POSTOPERATIVE PULMONARY DYSFUNCTION 
Pulmonary dysfunction, defined as the reduced ability of the lungs to exchange 
gases, such as oxygen, is one of the most common complications following cardiac 
surgery (8). Up to 90% (29) of patients can develop pulmonary dysfunction for at 
least one week after uncomplicated surgery (7). 
The dysfunction can be caused by many factors and can be divided into poor 
postoperative lung mechanics and abnormal gas exchange. (30) Alterations in the 
lung mechanics may be attributed to the surgical factors per se (e.g. impaired 
movement of the chest after sternotomy, pulmonary oedema drain discomfort, and 
wound pain), while the abnormal gas exchange (CO2, O2) may be attributed to the 
anaesthesia, lung collapse or atelectasis, and the use of CPB.  
Despite improvements in the CPB techniques, the use of the artificial circuit usually 
leads to a systemic and pulmonary inflammatory reaction. This, in combination with 
the alveolar collapse, induces dysfunction in the alveolar-endothelial barrier, with 
subsequent intrusion of oedema fluid in the lungs. As a consequence, lungs are 
injured and the normal gas exchange is impaired. (8) Clinically, these alterations are 
indicated by respiratory difficulties, changes on chest radiographs, low arterial 
oxygen levels, and cough. (6)  
1.2.1. GAS EXCHANGE 
The gas exchange (Figure 1-2) is determined by quantifying the partial pressure of 
oxygen (PaO2) in arterial blood (7) or by taking the ratio between PaO2 and the 
fraction of inspired oxygen (PaO2/FiO2). PaO2 is a measure of the amount of oxygen 
that binds to haemoglobin. The higher the pressure, the more oxygen is bound to 
haemoglobin, and the more oxygen is transported to the tissues. Under normal 
conditions, approximately 97-98% of the oxygen is attached to the haemoglobin 
molecules in the red blood cells, while the remaining oxygen dissolves in the 
plasma. Depending on the body environment, the tissue demand, and the number of 
haemoglobin molecules, oxygen dissociates from haemoglobin when needed.(31) 
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Figure 1-2  The gas exchange across alveoli. Each lung is made up of millions of 
alveoli. Capillaries surround each cluster of alveoli and ensure proper gas 
exchange between the air and the blood. Under normal conditions oxygen moves 
from the alveoli to the bloodstream, and further on to the body tissues and cells in 
exchange for carbon dioxide. Copyright © 2006 by Encyclopaedia Britannica, Inc.                                                                                                                                            
All patients exhibit some decrease in the alveolar gas exchange immediately after 
surgery (32). Hence, the percent of O2 delivered by haemoglobin to tissue is lower 
than normal (31). Gas exchange is abnormal when the PaO2/FiO2 is below 40kPa (or 
below 300mmHg) or when the PaO2 is below 8.4kPa (or below 63mmHg). The 
lower the values, the more affected the lungs. (8, 10, 26)  
In order to increase, stabilize, and ensure adequate oxygen delivery to vital organs, 
supportive oxygen (e.g. mechanical ventilation) is given following surgery. Despite 
oxygenation, some patients do not respond to the intervention and develop lung 
injury with compromised oxygen delivery to the pulmonary capillary.(8) As a result, 
blood oxygen content will drop (hypoxaemia) and cells and tissues may experience 
low oxygen levels (hypoxia). If unresolved, it may eventually lead to cell death and 
organ failure. Evidence suggests that the brain is the organ most exquisitely 
sensitive to injury from low intracellular PaO2 (< 3 minutes), followed by kidney, 
liver, and muscles. (33, 34)  
The degree of hypoxaemia is determined by arterial blood gas analysis. The lower 
the PaO2 values the more severe the hypoxaemia (Figure 1-3)(35). Hypoxaemia may 
vary from mild decreases, requiring only a short period of mechanical ventilation, to 
severe decreases, causing difficulties in breathing, excessive cough, prolonged 
mechanical ventilation, pulmonary infections, and requiring longer hospitalization 
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(36). In severe cases, patients may develop acute respiratory distress syndrome 
(ARDS) or its milder form, previously termed acute lung injury (ALI). Although the 
occurrence of postoperative ARDS is relatively low (< 3%) (8), the syndrome is 
devastating, with significant morbidity and mortality (40-80%) (8, 37-39). 
 
Figure 1-3  The haemoglobin oxygen dissociation curve demonstrates how the 
oxygen saturation of haemoglobin (SaO2) varies with the levels of the partial 
pressure of oxygen (PaO2). Risk categories are overlaid on the curve. Normal 
arterial PaO2 levels are above 80 mmHg, while normal SaO2 ranges from 93-97%. 
At low PaO2 the haemoglobin binds to fewer O2 molecules, and patients suffer from 
severe hypoxaemia. As the PaO2 increases the haemoglobin molecule binds to more 
O2 molecules, causing the steep part of the curve as the PaO2 goes from 15 mmHg to 
60 mmHg. As PaO2 increases, the level of hypoxaemia decreases. From 60 mmHg to 
80 mmHg more O2 binds to haemoglobin and fewer binding sites become available. 
Above a PaO2 of 80 mmHg the slope of the curve becomes nearly flat, and at a PaO2 
of 100 mmHg the haemoglobin is 97-98% saturated. The flat upper portion of the 
curve represents the PaO2 entering the lungs exceed the oxygen concentration in 
blood returning to the lungs; and thus, the oxygen binds easy to the haemoglobin. 
Copyright © 2011 by the American College of Emergency Physicians.  
Because all patients present decreased oxygenation right after surgery, it is difficult 
to recognize progressive hypoxaemia and the severity of forthcoming pulmonary 
insufficiency. Also, it is still not known why certain patients develop hypoxaemia, 
whilst others do not. (8) Several studies have shown that patients do not necessarily 
develop hypoxaemia during the first postoperative hours, but rather during the 
second to third postoperative day (30, 32, 40-42). In a study conducted by Singh and 
co-workers (30) serial arterial blood gas measurements obtained on days 1, 2, 4, 6, 
and 8 postoperatively revealed a drop in the PaO2 levels at all time points compared 
to the preoperative values, with the lowest values on the second postoperative day. 
Same decreases were reported by Rasmussen and colleagues (41, 42), with lowest 
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PaO2 values on the third postoperative day. Although PaO2 improved the following 
days, impaired oxygenation can persist for up to two weeks postoperatively (43). 
Since hypoxaemia extends hospitalization and increases the risk of various 
complications, as well as mortality, it is important to understand the risk factors and 
the mechanisms leading to its progression. (26, 44)  
1.2.2. RISK FACTORS FOR PULMONARY DYSFUNCTION  
Many factors are implicated in the development of postoperative lung injury; hence, 
knowledge about possible predictors of hypoxaemia is a prerequisite for risk 
stratification of patients.  
1.2.2.1 Preoperative factors  
A neglected but crucial factor of postoperative pulmonary dysfunction is patients’ 
medical history before surgery (25, 45). Older (6, 38), sicker (6, 25, 38) and more 
obese (26) patients, with a history of smoking (6, 26) have a higher risk of 
developing postoperative pulmonary dysfunction. In addition, some patients are 
more genetically predisposed to produce greater inflammatory responses to severe 
trauma such as CPB, and thus, to progress to lung injury. Studies have shown that 
polymorphisms in the pro-inflammatory interleukin-encoding genes of IL-6 and IL-
18 could predispose patients to develop post-CPB ALI/ARDS. (14-16) 
1.2.2.2 Intra- and postoperative factors 
A combination of many factors unique to cardiac surgery is reported to be attributed 
to the development of poor lung function and impaired gas exchange. Among the 
most significant are general anaesthesia (6, 46), sternotomy (6), atelectasis, contact 
of blood components with the artificial surface of the CPB circuit, blood exposure to 
the different shearing forces within the CPB (12), ischemia–reperfusion (13, 14), 
and endotoxemia (47).  
Studies have shown that anaesthesia during surgery temporarily decreases PaO2 due 
to relaxation of the chest wall, affecting the lung capacity and lung mechanics. In 
addition, sternotomy is believed to affect muscle tone of the chest wall and proper 
ventilation. Also, the cold topical solutions given to protect the heart may induce 
damage to the respiratory nervous system and may cause postoperative respiratory 
distress. Furthermore, the deflation and the time of inactivity of the lungs may cause 
postoperative partial atelectasis, causing partial closure of the alveoli, 
inhomogeneous airway constriction, and concomitant impairment in the alveolar 
function of gas exchange. (6, 8, 46) 
The passage of blood through the circuit induces an acute phase reaction that can 
lead to a systemic inflammatory response. Since the lungs are the filters of the 
venous circulation, and since the pulmonary capillaries are smaller in diameter than 
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the systemic capillaries, substances produced during CPB may aggregate, or may be 
trapped, when passing through the pulmonary microcirculation. Hence, it may affect 
the lungs more than other organs, leading to lung injury with subsequent impaired 
gas exchange caused by: endothelial cell swelling; plasma and proteins intrusion 
into the interstitial space between capillaries and alveoli; and congestion of the 
alveoli with oedema fluid.(8)  
To reduce the pulmonary dysfunction associated with CPB, the number of off-pump 
CABG has increased in the last 25 years. Follow-up studies have shown that while 
the off-pump CABG may attenuate the levels of IL-8 and IL-10, the procedure does 
not necessarily improve postoperative oxygenation (41), nor does it lower the 
mortality rate among patients (22, 48). Also, while some studies have shown 
predictive association between the time on CPB and the later postoperative 
hypoxaemia (36, 44), others have not found this association (26).   
Higher intraoperative use of fluids during CPB has also been associated with an 
increased risk of pulmonary oedema formation, and thus, increased risk of 
postoperative hypoxaemia (44). Patients often require blood products during and 
after surgery to replace their blood loss, and these products carry the risk of 
transfusion-related ALI. (12)  
Furthermore, studies have reported that during surgery microorganisms and their 
endotoxins enter the blood stream and induce further complications. They may 
originate from the surgical materials used (instruments, gloves, oxygenator), the 
fluids used, the blood transfusion, drugs, the ice for external cooling of the heart, or 
the translocation of bacteria from the intestinal flora into the bloodstream, among 
others. As a consequence, endotoxins bind to various receptors on inflammatory 
cells, causing an escalation in the production of pro-inflammatory mediators.(14, 47) 
Lastly, for some patients, inappropriate oxygen supplementation and mechanical 
ventilation given during and after the surgery can be harmful, leasing to oxygen 
toxicity, rupture of the alveoli during lung stretch, and subsequent ventilator-induced 
lung injury. (33, 34) 
1.2.3. MOLECULAR MECHANISMS OF PULMONARY DYSFUNCTION 
Although only a small part of the mechanisms involved in the development of 
postoperative pulmonary dysfunction is known, current evidence reveals increased 
damage to alveolar cells, neutrophil infiltration, and increased microvascular 
permeability. (8, 49)  
1.2.3.1 The systemic inflammatory response  
Although the surgical procedure saves lives every day, the contact of blood with the 
CPB circuit activates the inflammatory cascade and initiates a systemic acute phase 
reaction (8, 25). Cytokines play an important role in this cascade, either as pro-
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inflammatory (e.g. tumor necrosis factor-α, TNF-α; IL-2, IL-6, IL-8; and platelet-
activating factors, PAF) or anti-inflammatory mediators (e.g. IL-1 and IL-10). Under 
normal conditions, the balance between pro- and anti-inflammatory cytokines is 
essential to avoid inflammation. This balance is shifted towards the production and 
activation of pro-inflammatory mediators after CPB.(14, 50)  Pro-inflammatory 
mediators activate a large variety of cell types in the blood, including neutrophils, 
leukocytes, monocytes, macrophages, and lymphocytes, recruiting them to the lungs. 
These cells bind to adhesion molecules on the surface of capillary cells and migrate 
into the interstitial fluid space of alveoli, where they release proteolytic enzymes and 
reactive oxygen species (ROS) such as superoxide anions, peroxides, hydroxyl 
radicals). (49) 
1.2.3.2 The ischemia-reperfusion mechanism 
During CPB the lungs are almost excluded from the circulation and the blood 
remains almost stagnant inside them for up to several hours. Consequently, the lungs 
experience ischemia and an increased demand of oxygen.(8) Since cells cannot 
maintain the necessary energy supply, they compensate by degrading adenosine 
triphosphate (ATP) to adenosine, inosine, and hypoxanthine. During ischemia these 
by-products accumulate. Decreased ATP levels inactivate the cellular membrane 
pumps and ions are thus freely to move across the membranes. Moreover, due to the 
anaerobic environment, lactate accumulates and intracellular pH decreases, causing 
acute cellular swelling and even cell death. (14)  
At the end of surgery, lungs are re-expanded and blood flow and oxygen supply 
returns (reperfusion). Although oxygen is necessary for cell salvage, the reperfusion 
process creates more injury than ischemia itself, culminating in damage to the DNA, 
proteins, carbohydrates, and lipids. When oxygen is reintroduced in the lungs, 
xanthine oxidase converts the accumulated hypoxanthine to uric acid and produces 
superoxide anions. Superoxide anions are converted by superoxide dismutase to 
hydrogen peroxides, which bind to free iron, producing hydroxyl radicals. These 
radicals are highly destructive and potent oxidizing agents that react with almost 
every molecule in the cell, including lipids. Lipid peroxidation products enhance the 
ongoing inflammation; damage the cell membrane; lead to the loss of cellular 
membrane stability; affect proper functioning of the enzyme systems and receptors; 
alter the ionic channels; and increase cellular permeability, finally leading to cell 
death and even organ dysfunction. (14, 27, 49)    
Hence, the combination of imbalanced inflammatory responses, the adverse effects 
of pulmonary ischemia-reperfusion, the possible swelling of the capillary cell 
membrane, the fluid accumulation in the interstitial space, and the intrusion of 
protein-rich oedema fluid in the lungs leads inevitably to impaired gas exchange and 
deterioration in the respiratory mechanics of the lungs. (8)  
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1.2.4.  DETECTION OF PULMONARY DYSFUNCTION 
Despite the known mechanisms, early detection of patients developing postoperative 
pulmonary dysfunction can be challenging (39, 51). Currently, there is no early gold 
standard diagnostic test for the quantification of postoperative pulmonary 
dysfunction (52), and the PaO2 values used to assess the degree of lung injury cannot 
be used to predict the progression to hypoxaemia. Roe and co-workers (53) have 
associated the PaO2 values measured before and during surgery with the 
postoperative PaO2 values in a group of patients suffering from postoperative 
hypoxaemia. Poor predictive association was detected, indicating that prior 
knowledge about the gas exchange is not a good prognosticator of later hypoxaemia.   
In addition, there is no treatment option (9) and no molecular-driven intervention 
(39, 51) to prevent the progression into pulmonary dysfunction. When lung injury is 
present, supportive care and conservative fluid management is given to the patients 
(39, 51, 54). If patients do not improve upon management, multiorgan dysfunction 
may develop, and patients may die. On the other hand, if patients survive, they 
recover gradually; with many patients continuing to have persistent pulmonary 
abnormalities for longer periods of time.(55)  
1.2.5. BIOMARKERS OF PULMONARY DYSFUNCTION 
Early identification and stratification of patients at risk of developing pulmonary 
dysfunction is an area of great research.  
A biomarker can be anything (e.g. vital sign, laboratory value, and finding on an 
image) that shows association to a disease, is relatively stable, sensitive, specific, 
and can be useful for screening, diagnosis, and monitoring of the effect of initiated 
therapies. A predictive biomarker is a marker that can spot at-risk patients before the 
symptoms are detectable, and that may help in the development of therapeutics 
targeting disease progression. (52, 56) 
Biomarkers, whether measured in blood, urine, or exhaled breath, have found 
limited use for the early identification of patients developing postoperative 
pulmonary dysfunction (52). A possible explanation for this might be the complex 
nature of chain reactions that sequentially or in parallel activate molecules during 
and after surgery. Since ALI/ARDS is the most severe form of pulmonary 
dysfunction, studies have focused on identifying markers that could be used for 
diagnostic purposes and for the prognostication of patients’ outcomes.(56) 
Inflammatory markers (IL-6, IL-8, TNFr-1 and -2, urine nitric oxide NO), epithelial 
cell markers (receptor for advanced glycosylation end-products RAGE, surfactant 
proteins), adhesion molecules (intercellular adhesion molecule ICAM-1), markers of 
endothelial injury (von Willebrand factor antigen), extracellular matrix (desmosine), 
and coagulation proteins (protein C, plasminogen activator inhibitor PAI-1) were all 
associated independently with mortality in diagnosed ALI/ARDS patients.(52, 57-
62) Procollagen peptide III has been shown to be correlated with patients’ outcomes 
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(62). A few of these markers (SP-D, IL-6, IL-8, protein C, RAGE, and urine NO) 
had shown modest association with the effect of ventilator treatment, however, they 
were too weak to be used in monitoring the effects of treatment.(63) Fremont and 
co-workers (64) have found that by combining seven of the known inflammatory 
markers (brain natriuretic peptide, RAGE, procollagen peptide III, angiopoietin 
Ang-2, IL-8, IL-10, and TNF-α) trauma-induced ALI patients could be differentiated 
from non-ALI patients.  
While these markers were found in the general patient population of ALI/ARDS, 
only soluble sRAGE has shown predictive value in patients undergoing cardiac 
surgery with the use of CPB (65, 66). Plasma sRAGE was found to be predictive for 
pulmonary dysfunction immediately after end surgery in young children (65). In an 
adult population, increased plasma concentrations of sRAGE were found to 
associate with lower PaO2/FiO2 values, longer mechanical ventilation, and longer 
ICU stay.(66) More recently, small molecules such as fatty acids were also found to 
be predictive of postoperative pulmonary dysfunction. Sheng and co-workers (17) 
have reported that increased levels of free fatty acids in blood collected 2 hours after 
end CABG could predict patients developing hypoxaemia (r = -0.367, p< 0.001). In 
addition, they found a positive correlation between free fatty acid and the 
endothelial activator marker ICAM-1, indicating their possible role as early 
biomarkers of lung injury.(17)  
These biomarkers are crucial for the early identification of patients who are likely to 
develop lung injury. Recognizing the dysfunction before finding that the patient 
cannot ambulate due to symptomatic shortness of breath or hypoxaemia would 
lower mortality rate among patients, and would improve patients’ outcomes 
postoperatively.(6) While these studies are crucial for the early prognostication of 
at-risk patients, there is still need for more research-based knowledge, to gain a 
deeper understanding of the molecular reasons for the development of postoperative 
pulmonary dysfunction.  
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CHAPTER 2. AIMS OF STUDY  
2.1. PREVENTING PULMONARY DYSFUNCTION 
Preventing postoperative pulmonary dysfunction is a desirable goal since it can 
cause increased morbidity and mortality, and its treatments are expensive. Because 
some degree of postoperative hypoxaemia is expected, the question of which 
patients will develop pulmonary dysfunction is difficult to answer (6, 8).  
To make progress, we need to improve the current knowledge of the molecular 
mechanisms involved in the development of pulmonary dysfunction. We propose 
that metabolites may contain valuable information that will help us to answer this 
question. Since metabolites are the end products of transcripts and protein 
regulation, they change rapidly upon perturbations such as anaesthesia, sternotomy, 
the use of CPB, and medication. Therefore, mapping the metabolic changes during 
and in the early postoperative period could offer new insights into the chemical 
processes involved in disease progression.  
Nuclear magnetic resonance (NMR) spectroscopy has previously been applied to 
measure the levels of tens to hundreds different metabolites in a biological sample. 
Since the technique has shown applicability in biomarker discovery (67-72), we 
hypothesized that NMR could be used to identify possible mechanisms involved in 
the development of postoperative hypoxaemia.   
2.1.1. STUDY DESIGN AND RESEARCH QUESTIONS 
This study was designed to address the effect of the surgical procedure on the human 
metabolome, and to address the metabolic interactions and their changes over time 
in relation to the progression into hypoxaemia. Thus, this study attempted to build 
models that would predict outcomes and to answer the following research questions: 
1. How does the surgical procedure affect the levels of metabolites? 
2. Can metabolites be used to detect early signs of postoperative hypoxaemia?  
3. Which mechanisms are involved in disease progression? 
2.1.2. POSSIBLE OUTCOMES  
By answering these questions, we aim to gain a better understanding of the 
mechanisms involved in the progression of hypoxaemia. Such knowledge may be 
valuable to the clinicians to diagnose the dysfunction earlier in its course, may 
improve morbidity, may lower the mortality among patients, and may improve 
treatment options.  
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2.1.3. METHODOLOGY   
To answer these questions, fifty patients who underwent CABG with the use of CPB 
at Aalborg University Hospital were recruited. Thirty two patients showed moderate 
to severe signs of hypoxaemia (PaO2/FiO2< 40 kPa), whilst eighteen showed no sign 
of hypoxaemia (PaO2/FiO2≥ 40 kPa) on the third day postoperatively. Their blood 
samples were collected at ten different time points before, during, and after end 
surgery. Nearly 850 blood samples were prepared and more than 1600 spectra were 
analysed by NMR and multivariate data analysis.  
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CHAPTER 3. METABONOMICS   
As with most conditions, outcomes are influenced by genetic makeup, 
environmental factors, and treatment options. While several studies have been 
conducted to detect the risk factors and to identify the affected genes and proteins 
that may trigger the progression into postoperative pulmonary dysfunction, little is 
known about the metabolic states in these patients.  
3.1. METABOLITES   
Metabolites are the endpoint of genes, transcripts, and protein regulation and 
comprise all the low-molecular weight molecules (<2000 Daltons) present in a cell, 
tissue, or organism (73). Since metabolites respond to environmental perturbations 
(e.g. disease progression, toxic exposure, drug treatment, dietary change, and genetic 
manipulation (73-75)) long before the upstream processes, they carry valuable 
information regarding what is happening in the biological system (76).  
The precise number of metabolites is still unknown, however, over 40,000 
metabolites were annotated in 2013 in The Human Metabolome Database (HMDB 
v.3.0), and the number is expected to grow (73). There are two types of metabolites: 
primary and secondary. Primary metabolites are the building blocks of DNA, 
mRNA, and proteins. They are involved in regulatory processes and synthesis of 
cellular energy, and are thus considered essential for life. Examples of such 
metabolites are amino acids, carbohydrates, ketones, alcohols, glycoproteins, sugars, 
lipids, vitamins, antioxidants, organic acids, and nucleotides. Secondary metabolites 
are important in the defence system. Examples of secondary metabolites are 
pigments, sterols, toxins, drugs, and chemicals that humans ingest or come into 
contact with.(73, 77)   
Metabolites are very heterogeneous, encompassing both volatile and non-volatile 
compounds. Their concentrations range from femto- to millimol, and are highly 
dependent on the physiological state of the biological system, i.e. the environmental 
perturbations, and the activity of all the enzymes involved in the synthesis and 
conversion of one specific metabolite. (78) Metabolites are highly interconnected, as 
one metabolite can participate in only one, or multiple, different reactions. This 
ensures a highly complex metabolic network of tightly regulated reactions.(79) Even 
small perturbations in the genome, transcriptome, or proteome can create significant 
changes in the levels of many metabolites.(76, 79)  
Due to this interconnectivity and their prompt response to perturbation, metabolites 
are considered to be the cellular fingerprints of ongoing processes in our biological 
system (80), and thus, they might be the best molecules to explain disease 
mechanisms (75). This makes metabolite analysis attractive for medical purposes, 
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where the goal is to understand diseases, identify biomarkers, evaluate responses to 
therapies, and identify potential drug targets (79, 81). 
Several studies have demonstrated metabolites’ reproducibility and predictive 
powers in complex diseases. Examples of metabolites routinely used as biomarkers 
in the clinic include: creatinine to detect kidney disease; glucose to diagnose 
diabetes; cholesterol and triglycerides to determine the risk of CAD; and thyroxine 
hormone to detect hypo- and hyperthyroidism.  
3.1.1. THE HUMAN METABOLOME  
The complete collection of all metabolites in the body represents the human 
metabolome. In comparison, the complete set of genes inside a cell defines the 
human genome, the RNAs produced by the genome represent the transcriptome, and 
the set of all proteins in the system defines the proteome. Together, they define who 
and what we are (Figure 3-1).(73, 76)  
 
Figure 3-1 Interaction of the metabolome with genome, transcriptome, proteome, 
and their relationship to the phenotype. Each ‘–ome’, with the exception of the 
genome, is a complex function of the other -omes, and the amount of integration 
increases from the genome to the metabolome. In addition, the environmental 
impact on each –ome increases from the genome to the metabolome (after Lewis et 
al., 2008 (82)). Of note, the number of identified metabolites has increased since the 
publication of this figure (in 2008) by over 1300% (73) (in 2013). 
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While the genome can be described by 4-letter codes for genes, and the proteome by 
20-letter codes for proteins, the metabolome itself is more diffuse and not easily 
defined (75). Also, the metabolome is not solely dictated by genes, proteins, and the 
environment (what we eat, breathe, drink), but also by the microflora that live inside 
our body. Hence, the contribution of all these compounds together with their 
heterogeneity makes the characterization of the metabolome challenging.(73) 
3.2. METABOLOME ANALYSIS 
The approach that quantifies metabolic responses to various biological and/or 
environmental perturbations is called ‘metabonomics’ (83, 84), while the approach 
that aims at measuring all metabolites under homeostatic conditions is termed 
“metabolomics” (85, 86).  
Although the terms are now often used interchangeably, they have slightly different 
aims and historical origins. While metabonomics was introduced by Prof. Jeremy 
Nicholson in 1999 (83) and had its foundations in toxicology studies of mammalian 
systems, metabolomics was launched a year later by Prof. Oliver Fiehn (85) and had 
its origin in plant and microbial sciences. Metabonomics aims to find insights into 
the actual phenotype of a disease and the causes of its progression, while 
metabolomics aims to find the common metabolic phenotypes of biological systems 
at the time of sample collection.(76) In the last two decades both approaches have 
evolved and expanded, and nowadays, they are inseparable parts of the integrated 
systems biology strategies, together with genomics, transcriptomics and proteomics.  
Metabonomics has gain significant attention in many areas of medical research (87). 
Especially, the approach has great potential for intensive care medicine, where 
diseases are complex, and where understanding the relationship between host 
factors, disease, and effect of treatments is highly desirable (88). Some of the 
clinical applications of the approach have been in characterizing the metabolome of 
patients diagnosed with ALI/ARDS (67, 69, 89, 90), cardio-vascular disease (91), 
type-2 diabetes (92), liver disease (93, 94), preeclampsia during pregnancy (95), 
cancer (68, 70, 72, 96), and neurodegenerative disorder (71, 97-99).  
3.2.1. ANALYTICAL TECHNIQUES  
Metabolomics/metabonomics analysis is highly dependent on the analytical 
technology used. Due to the large number of metabolites and their heterogeneous 
nature, there is no single analytical technique that can capture the entire 
metabolome’s complexity. There are, however, several techniques that are 
applicable for the purpose of characterizing part of the metabolome, as they can 
measure tens to thousands of metabolites in a sample. Such techniques include 
nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) coupled 
to different separation techniques, Fourier transform infrared (FTIR) spectroscopy, 
Raman spectroscopy, and electrochemical array, among others. Each technique has a 
different selectivity, sensitivity, speed, need for sample pre-treatment, and degree of 
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difficulty in data pre-processing. Since FTIR, Raman and electrochemical array 
cannot offer detailed metabolic identification, they are less used in metabolomics/ 
metabonomics research. On the other hand, NMR and MS offer the capacity to both 
identify and quantify metabolites, and are thus frequently used for metabolome 
characterization.(78) 
Both NMR and MS offer platforms that obtain rich information from a broad range 
of biological samples (e.g. serum, urine, saliva, bronchoalveolar lavage fluid BALF, 
exhaled air, cerebrospinal fluid CSF, tissue) (88).   
NMR uses magnetic properties of nuclei to determine the structure and 
concentration of a metabolite. For metabolome analysis proton NMR (
1
H-NMR) is 
typically used. The technique involves the use of a large and powerful magnet (400-
1000 MHz) to obtain metabolic information. MS is a technique that identifies 
metabolites based on the detection of the mass/charge ratio (m/z) of ions produced 
by ionization of chemical compounds. Molecules in a sample are vaporized before 
being ionized. Thus, molecules are broken into charged fragment and these can then 
be sorted and detected based on their m/z. To improve ion separation, MS can be 
coupled to chromatographic techniques. Typically the separation is performed using 
gas chromatography (GC), liquid chromatography (LC), high-performance LC 
(HPLC), ultra-HPLC or capillary electrophoresis.(100) During GC, molecules are 
separated in gaseous phase before they are sent to the ion source; while during LC 
molecules are separated in a liquid phase by the chromatogram prior to 
ionization.(82, 87, 88) A comparison between the advantages and disadvantages of 
NMR and MS is given in Table 3-1.  
With the exception of NMR, most techniques, including MS, need sample 
preparation prior to analysis. NMR is unique in being suitable for measuring 
complex samples (e.g. blood, urine, tissue) with little or no prior preparation (101). 
The technique offers the possibility of measuring a wide range of metabolites arising 
from very different parts of the metabolic network (e.g. amino acids, lipids, 
carbohydrates, glycoproteins, ketones, alcohols, etc.) (102). Since most of the 
central nodes within the metabolic networks are 'NMR visible', and since these 
nodes are highly interconnected (103, 104), the technique offers the possibility of 
indirectly detecting a large number of metabolic perturbations (102, 105). The 
biggest disadvantage of NMR is its poor sensitivity (>1μM (78)) compared to MS 
(106). 
Unlike NMR, sample preparation for MS requires sample separation (e.g. extraction 
or derivatization), which can introduce laboratory biases. Since MS is usually placed 
after a chromatography step, some metabolites will not be able to reach the detector 
and therefore further biases can be introduced in the analysis. However, MS is much 
more sensitive than NMR, being able to detect very low metabolic concentrations 
(78).  
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Table 3-1: A comparison of the NMR and MS techniques used for metabolomics/ 
metabonomics studies (after ref.(100, 102-107)). Abbreviations: GC, gas chromate-
graphy; LC, liquid chromatography; NMR, nuclear magnetic resonance.  
Technology Advantages Disadvantages 
NMR  Quantitative  
Good reproducibility  
Non-destructive  
No separation needed  
Fast (2-3 min/sample)  
Cheap on a per-sample basis 
Measures liquids and solids   
Allows identification of new 
metabolites 
Not very sensitive  
Expensive instrumentation  
Requires larger sample volume  
(> 0.3 mL) 
GC-MS  Quantitative  
Good reproducibility  
Good sensitivity  
Relatively inexpensive  
Modest sample size needed  
Sample not recoverable  
Extensive sample preparation  
Slow (20-30 min/sample) 
Difficult metabolite identification  
Only applicable for vaporizable 
metabolites 
LC-MS High sensitivity  
Minimal sample volume   
Potential to detect the largest 
portion of the metabolome 
Sample not recoverable  
Less reproducible  
Expensive instrumentation  
Slow (20-30 min/sample)  
Difficult metabolite identification  
 
3.2.2. APPROACHES FOR DATA ANALYSIS  
Regardless of the technology used, metabolomics/metabonomics data comes as a 
collection of unassigned peaks with varying intensities and information about 
chemical shifts (for NMR data), the retention times (for LC or GC data), and masses 
or mass fragments (for MS data). These peaks must be subjected to different 
approaches I order to interpret the biological information.  
There are two types of approaches: targeted and untargeted. The targeted approach 
focuses on analysing one or several selected metabolites related to a specific 
pathway, while the untargeted approach measures all detectable compounds in a 
sample. The targeted approach does not intend to detect novel metabolites in a 
sample, and it is thus mainly used to test specific hypotheses. The untargeted 
approach aims to detect novel biological information and is often used in 
hypothesis-generating studies.(87) The approach can be further divided into 
fingerprinting and profiling.  
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Metabolite fingerprinting is an untargeted, high throughput, global analysis of 
samples which provides a global snapshot or ‘fingerprint’ of the metabolome 
without precisely quantifying or identifying the chemical compounds in the sample. 
This approach is based on ‘chemometrics’, a statistical comparison of spectral 
intensities with the aim of identifying spectral features or patterns that discriminate 
between samples (e.g. case/control). Metabolite fingerprinting is powerful, rapid, 
and is suitable as a screening tool for diseases. Metabolic profiling is more 
challenging than fingerprinting, since it is based on identification and quantification 
of a set of metabolites in a biological sample. This approach is also called 
‘quantitative metabolomics/metabonomics’, and it can be either targeted or 
untargeted.  
Both approaches have advantages and disadvantages, and their choice depends on 
the problem to be solved. Although fingerprinting is applied to a wider range of 
metabolites, a greater understanding of the underlying mechanisms of action can be 
achieved when combining fingerprinting with profiling. While fingerprinting can be 
used to investigate different metabolic phenotypes (e.g. healthy/disease states), 
metabolic profiling can then be used to provide detailed information about the 
specific differences between the two phenotypes. In this way, the metabolic 
signature differentiating the experimental groups can be detected, and the 
metabolites causing this differentiation can be identified and quantified. (75, 78) A 
combination of both approaches has been chosen for this PhD study. A collection of 
some terminologies are presented in Table 3-2.  
Table 3-2: Definitions of terms used in metabolomics/metabonomics studies. From 
ref. (79, 81, 106, 108). 
Terms Definitions 
Metabolome    The complete set of all primary and secondary metabolites  
Metabonomics   Quantitative analysis of metabolite changes in response to 
biological and environmental perturbations 
Metabolomics Identification and quantification of metabolites in a 
biological system under homeostatic conditions 
Metabolic profiling   Identification and quantification of a group of predefined 
metabolites (e.g. carbohydrates) 
Metabolic 
fingerprinting 
A global analysis of samples that provides a snapshot or 
‘fingerprint’ of the metabolome without precisely 
quantifying or identifying the metabolites in the sample 
Metabolic footprinting   Analysis of the metabolites secreted or excreted by an 
organism (i.e. bacteria) in a growth medium or 
extracellular fluid. 
Metabolic phenotypes  
(metabotypes) 
Represent deviations from the optimal condition (i.e. 
homeostasis, steady state) and can be used as indicators of 
an individual’s health state. 
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Fluxomics (metabolite 
flux analysis) 
Analysis of labelled metabolites by their conversion 
through metabolic pathways.  
Lipidomics Analysis of lipids and their interactions in a biological 
system. 
 
3.2.3. METABONOMICS IN ACUTE LUNG DISEASES 
Metabonomics work relevant to lung diseases is in infancy. Only a small amount of 
work has been carried out focusing on pneumonia and ALI/ARDS (87, 88), and no 
study has been conducted on patients at risk of developing lung injury after CPB. 
3.2.3.1 Pneumonia 
Pneumonia is a common acute lung inflammatory disease affecting millions of 
people every year (87). The disease is the leading cause of death among young 
children globally (109). Since pneumonia is caused by different microbial organisms 
(e.g. bacteria, viruses, fungi, and parasites) it can be difficult to identify the 
pathogen(s) responsible for the disease. Hence, it often leads to delays in appropriate 
antimicrobial therapies. Metabonomics could possibly help to accurately identify the 
cause, and to monitor disease progression or regression.(110)  
NMR-based metabonomics analyses performed on urine samples from human (110) 
and mice (111) with pneumonia have identified distinct metabolic profiles based on 
bacterial strains or viral infections. Patients with Streptococcus pneumonia could be 
differentiated from controls through metabolites such as glucose, lactate, citrate, 
succinate, acetate, acetone, and several amino acids (110). Serial collection of urine 
samples over time showed how the metabolic profiles changed upon resolution from 
the infection (111). A study using the MS approach on plasma and urine collected 
from children with pneumonia (109) has supported the concept of applying 
metabonomics analysis to diagnose community-acquired pneumonia. Although the 
study was small (only 11 children with pneumonia), they found similar results as the 
previous study.  
3.2.3.2 ALI/ARDS 
ALI/ARDS is an acute lung injury syndrome that can be triggered by different 
factors (e.g. cardiac surgery (8, 37-39), pneumonia, sepsis, and severe trauma (87)). 
Patients with ARDS are critically ill, requiring mechanical ventilation for several 
days. The mortality rate among patients is highly dependent on the triggering factor, 
and sepsis-induced ARDS is considered the leading cause of death. Despite the 
disease’ severity, knowledge of the pathogenesis of ARDS is incomplete, and to date 
there are no predictive biomarkers and no preventive pharmacotherapy.  
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Only few metabonomics studies have been performed to elucidate the metabolic 
phenotypes within ARDS, and currently, no study has found predictive biomarker 
for the development of ARDS.(87)  
In a metabonomics study performed on rats with ventilation-induced lung injury 
(VILI), a research group has found shifts in the energy metabolism (glucose, lactate) 
and a possible disruption of the cellular membrane integrity (glycine, phospholipids) 
(112). In a new study performed on serum from a rat model, Naz and co-workers 
(113) identified 18 metabolites to associate with VILI. In a study performed on male 
rats with lipopolysaccharide (LPS)-induced ARDS, Bos and colleagues (114) 
concluded that several exhaled volatile metabolites were predictive of the early 
development of lung injury (1 hour after the LPS exposure). Serkova and collegues 
(90) have investigated the metabolome of cytokine-induced ALI in a mouse model, 
and they found disturbances in the energy balance, decreases in the energy state 
(ATP), and increases in the glycolytic activity (lactate, glucose) in sick compared to 
control mice. 
The number of clinical studies on human models of ARDS is increasing. As early as 
1998, Schubert and colleagues (115) showed the utility of exhaled breath sample for 
GC-MS based metabonomics analysis in mechanically ventilated ARDS patients. 
They have found a more than 50% decrease in isoprene from exhaled breath of 
mechanically ventilated patients with ARDS compared to mechanically ventilated 
patients without ARDS. The utility of exhaled breath samples for ARDS 
metabonomics studies have been confirmed by Bos and colleagues (116), however, 
they could not confirm the results from the previous study. While the authors found 
three volatile compounds to be discriminative between ARDS and control subjects, 
they did not find any difference in isoprene levels. Recent data suggests that some 
metabolic levels vary greatly depending on the breath sampling method and the use 
of anaesthesia (117), thus, other, more stable, samples have been collected to 
achieve information of the local lung environment. BALF samples obtained through 
flashing the airways by a saline liquid were previously analysed. The metabolic 
profiles of sepsis-induced ARDS patients were compared to that of healthy control 
subjects, and nearly 50 metabolites were found to different between groups (118). 
Lastly, a small metabonomics study was also performed on plasma samples. Stringer 
and co-workers (119) compared plasma metabolic profiles of sepsis-induced ALI 
patients with healthy individuals, and found differences in the levels of glutathione, 
adenosine, myo-inositol, phosphatidylserine, and sphingomyelin.  
Taken together, these experimental and clinical studies indicate some perturbations 
in the levels of energy and oxidative stress metabolites, and show the potential of 
metabonomics to find some of the mechanisms involved in acute lung diseases.(119)   
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CHAPTER 4. METHODOLOGY, MATERIALS, 
AND METHODS  
Detailed descriptions of materials and methods are included in each paper. A 
summary and additional theory is provided below. 
4.1. METHODOLOGY 
The studies for this PhD thesis evolved as a part of continuing efforts to find 
predictive biomarkers for the progression to postoperative pulmonary dysfunction. 
This thesis is part of a study (registered at clinicaltrials.gov, NCT02475694) 
involving the characterisation of inflammatory mediators, coagulation factors, 
metabolites, and oxygen patterns in patients that have undergone cardiac surgery 
between September 2008 and March 2009 at Aalborg University Hospital in 
Denmark. 
4.1.1. STUDY POPULATION 
After ethical approval, a total of fifty consecutive patients scheduled for elective 
CABG with use of CPB were included in the study (Table 4-1). Inclusion criteria 
were adults above 18 years of age, on treatment with statins. Exclusion criteria were 
treatment with steroids or other immune suppressor therapies.  
Table 4-1 Patient characteristics. Annotations: n, number of subjects; SD, standard 
deviation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
CPB, cardiopulmonary bypass; PaO2, partial pressure of oxygen in arterial blood; 
FiO2, fraction of inspired oxygen (21%); Surgery, from skin incision to last suture. 
          All 
           (n= 50) 
Hypoxaemia 
(n= 32) 
Unaffected  
(n= 18) 
p-value 
Subject characteristics 
    Age, mean ± SD, years 65.8 ± 9.7 65.3 (48-83) 66.5 (48-81) -  
    Men, n (%) 41 (82) 23 (72) 18 (100) 0.01 
    BMI, mean ± SD, kg/m2 27.5 ± 0.2 27.2 ± 0.2 28.0 ± 0.3 - 
    Diabetes mellitus, n (%) 14 (28) 10 (31) 4 (22) - 
    Smokers(yes/no/ unknown)  16/30/4 11/19/2 5/11/2 - 
    COPD, n (%) 7 (14) 4 (13) 3 (17) - 
Surgical procedure, mean ± SD, min 
   Surgery  196 ± 50 207 ± 52 177 ± 38 0.04 
   Time on CPB  64 ± 29 67 ± 33 57 ± 21 0.23 
   Cross clamp  (Ischemia)  33 ± 19 37 ± 21 25 ± 11 0.03 
72 hours post-CPB, mean (range), kPa 
    PaO2  7.8 (10.7-4.9) 6.9 (8.4-4.9)  9.2 (10.7-8.6)   <0.0001 
    PaO2/FiO2  37.0 (51- 23.3) 33.1 (40-23.3)  43.9 (51-41) <0.0001 
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4.1.2. OUTCOMES 
After cardiac surgery, patients were transferred to the thoracic intensive care unit, 
under sedation, and mechanically ventilated. Patients were weaned from mechanical 
ventilation within the first 24 hours. The majority were discharged to the surgical 
ward on the first postoperative day, while four patients were discharged on the 
second postoperative day. Physiotherapy and supplementary oxygen were given to 
all patients on the surgical ward as standard care.  
A decrease in PaO2 was observed in all patients the three days following surgery. On 
the second and third day, several patients experienced hypoxaemia (48% and 64%, 
respectively). Hypoxaemia was defined by a PaO2/FiO2 below 40kPa or a PaO2 
below 8.4kPa. Because oxygenation worsened in some patients whiles in others 
improved within the second and third day (rp= 0.49, p= 0.0003), we defined patients’ 
outcome based on the third days PaO2 values. A total of thirty-two patients 
developed hypoxaemia, of which nine had severe hypoxaemia (PaO2/FIO2< 30kPa; 
PaO2< 6.3kPa), while eighteen showed no sign of hypoxaemia (PaO2/FIO2> 40kPa). 
In addition, the severe hypoxaemic group had more bilateral infiltrates on the chest 
images.  
4.1.3. CHRONOLOGY OF THE STUDIES  
Three patients were unable to provide samples at 16, 20, 48, and 72 hours post-CPB. 
Hence, a total of 832 plasma and serum samples were collected for this 
metabonomics study; 144 plasma samples were obtained from arterial blood the day 
before surgery, and 48 and 72 hours postoperatively; 688 serum samples were 
obtained simultaneously from the catheters inserted in the pulmonary artery (PA) 
and the left atrium (LA) after induction of anaesthesia. The serum samples were 
collected at seven different time points: after sternotomy, but before CPB; 
immediately after weaning from CPB (0 hours); and at 2, 4, 8, 16, and 20 hours after 
CPB. The aim of their collection was to investigate possible differences between the 
systemic (PA) and systemic + pulmonary microvasculature (LA). 
The overall hypothesis for this study was that early stages of hypoxaemia may be 
reflected at the metabolite level. Due to a lack of previous similar research, and due 
to the large number of samples to analyse, the first time point to analyse had to be 
chosen based upon clinical experience. The samples had to be relatively far from the 
surgical procedure, to avoid possible interference from anaesthesia and the surgical 
procedure, but they also had to be relatively far from the symptoms of hypoxaemia. 
Hence, we picked samples collected on the first postoperative morning (precisely 16 
hours after weaning from CPB). Because the results were positive, the analysis 
resulted in one publication (Study I, Appendix A). Also, since a biomarker signature 
was identified that could predict progression to hypoxaemia, a patent application 
was filed (Study IV, Appendix D).  
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The remaining samples, collected from nine different time points, resulted in a 
manuscript (Study III, Appendix C). The results confirmed the previous findings and 
identified several deranged mechanisms.  
Two additional studies were performed, aiming to characterize the coagulant and 
inflammatory mechanisms in these patients. The coagulation study resulted in a 
publication (Study II, Appendix B), while the inflammatory study is still ongoing.   
4.2. NMR-BASED METABONOMICS SAMPLE PREPARATION  
The main goal of NMR-based metabonomics studies is to identify metabolites that 
correlate to a specific disease. Since metabolites are prone to change even after 
small perturbations, the success of each study relies on consistency in sample 
collection and preparation. In the following section, some theoretical and practical 
aspects are presented concerning sample variation, NMR experiments, spectra 
processing, data analysis, and data interpretation.  
4.2.1. SAMPLE VARIATION  
Maintaining consistency in a sample set can be challenging, as several factors can 
affect the levels of metabolites. Studies have shown that pre-existing health 
conditions, diurnal variation, gender, age, diet, ethnicity, hormonal status, and 
exposure to stress factors affect the metabolome. Therefore, matching patients prior 
to the study is important (74, 120-122). This study was a retrospective study, and 
hence, selecting patients according to these recommendations was not possible. 
However, patients were relatively similar with regards to: their medical history 
(CAD), age, ethnicity (all Danish), body mass index, and the surgical procedure 
(Table 4-1). Also, since the surgical procedures were performed in the morning on 
fasting patients, both the variability arising from the diurnal effects and the diet were 
minimized. 
Plasma and serum specimens were obtained according to the routine hospital 
procedures. During this procedure some metabolic variation is inevitable, since 
some samples may be kept for a longer time at room temperature than others (123). 
This variation was minimized by having the same person prepare the samples, and 
by being consistent with the time a sample was standing at room temperature. 
Unfortunately, we did not have serum samples for all the time points. Since there are 
some metabolite differences between serum and plasma, some information was 
difficult to combine or compare in Study III. Serum is known to contain higher 
levels of several amino acids, phosphatidylcholines, and triglycerides, while plasma 
contains higher levels of lysophosphatidyl-inositol.(123, 124)  
Storing blood samples at -80
o
C has been shown to be the optimal choice for 
metabonomics studies (101, 124). Spectra of fresh plasma samples were compared 
to spectra of plasma stored for 9-13 months at -80°C, and it was found that sample 
storage did not influence the metabolite levels. Even a prolong storage of plasma 
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samples (2-15 years at -20°C) indicated that most metabolites were stable.(125) For 
this study, blood samples were stored for 2-3 years at -80°C prior to the NMR 
analysis, and therefore, it is assumed that possible metabolic variation from sample 
storage may be insignificant. 
4.2.2. SAMPLE PREPARATION   
One of the major advantages of NMR as a tool for metabonomics studies is its 
minimal requirements for sample preparation (101). For the metabonomics studies, a 
deuterated buffer was added to the samples to provide the necessary “deuterium lock 
signal” for data acquisition. 
4.3. DATA ACQUISITION BY NMR  
NMR spectroscopy is a powerful analytical tool that is well suited for analysis of 
different types of sample, including plasma (119, 126, 127), serum (126, 128), 
BALF (129), cerebrospinal fluid (130), pus (131), saliva (132), faeces (133), urine 
(126) and tissue (126). 
NMR was discovered in 1946 by two research groups (Bloch and Purcell) which, 
independently from each other, observed nuclear magnetic resonance signals for the 
first time. Their discovery was the subject of the Nobel Prize for Physics in 
1952.(134) After the discovery of the chemical shift (i.e. the observation that  the  
resonance  frequency  of  a  nucleus  is  affected  by  its  chemical  environment)  in 
1950, the technique quickly became significant as an analytical tool in chemistry. 
The first biological applications began in 1954, when a group at Stanford used 
proton (
1
H) NMR spectroscopy to show that DNA strands have large hydration 
shells (135). Three years later, biomolecular NMR had advanced to the stage where 
the first intact ribonuclease protein was examined (136). Since then, the field of 
NMR has evolved rapidly; from the first commercialized 60 MHz magnet capable of 
detecting only 
1
Hs, to today’s systems equipped with superconducting magnets 
operating at as high as 1000 MHz.(124) As a result of its continuously increasing 
application base, two more Nobel Prizes were awarded: one for the methodological 
development of high resolution NMR spectroscopy (R.R. Ernst in 1991); and the 
other for the development of NMR spectroscopy for determining the three-
dimensional structure of biological macromolecules in solution (Kurt Wüthrich in 
2002).(134) Also, a shared Nobel Prize (Paul C. Lauterbur and Peter Mansfield in 
2003) was given in the field of Medicine for the development of magnetic resonance 
imaging (MRI), derived from the NMR spectroscopy principles. Since then, MRI 
has become an invaluable diagnostic method in medicine.(137) Today, NMR has 
become one of the most powerful and flexible analytical techniques available in the 
field of chemistry, biology and medicine, including metabonomics. It is also one of 
the few methods that gives analytical information from deep within living cells, 
tissues, and biofluids with minimal or no sample preparation.(138) 
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4.3.1. THE PRINCIPLES OF AN NMR EXPERIMENT 
1
H NMR is a spectroscopic method based on the principle that protons resonate in a 
high magnetic field. The techniques uses radiofrequency (RF) waves to reveal 
information about magnetic nuclei in a compound. The information received 
consists of structural data and quantification data of molecules in a sample. (138) 
Running an NMR experiment is straightforward. Once the sample is prepared, it is 
placed in an NMR glass tube and put into an electromagnet, whose large coil 
generates a strong magnetic field (B0). Inside the magnet, another smaller 
electromagnetic coil exists, located at the end of a cylindrical probe, which sustains 
the sample. A high power, short duration, RF pulse produced by the probe coil 
irradiates the sample and the data acquisition process begins. The RF waves (or the 
magnetic field B1) have electrical and magnetic (electromagnetic) components that 
can flip nuclear magnetic moments from one spin state (+½) to another (-½). The 
more power applied to the RF waves, the more nuclei are flipped (a process called 
excitation). When the irradiating RF waves are turned off, the nuclei relax back to 
their original equilibrium state. During relaxation, they produce RF waves that 
provide information about the molecule(s) inside the sample. These RF waves are 
than collected as Free Induction Decays (FIDs) in the time domain, and are further 
Fourier transformed into the frequency domain. Here the signals are translated into 
peaks, displayed across a spectrum with units of parts per million (ppm) to 
distinguish their positions (i.e. chemical shift). The chemical shifts of these peaks 
are affected by the neighbouring chemical groups (nitrogen, oxygen, carbonyls, 
double bonds, halogens, etc.). Depending on the proximal electronegative group, 
each proton has its own unique position in the spectrum. Each proton resonance is 
further split by the interaction with protons on neighbouring NMR active nuclei. The 
area under the peak is directly proportional to the concentration of each metabolite, 
and hence, besides structural information, information about metabolite 
concentration is also obtained.(87, 138)   
4.3.1.1 One-dimensional experiments 
The bedrock of NMR-based metabonomics studies rely on one-dimensional (1D) 
experiments. These experiments are relatively fast, robust, and easy to implement, 
providing information about the concentration, the structure, and the position 
(chemical shift) of a metabolite in a spectrum (139). One-dimensional NMR spectra 
provide a global snapshot, or fingerprint, of the metabolome state, and are thus, 
typically used to evaluate metabolite alterations between groups or classes.(140)  
In most cases, samples are prepared in the solution state, which allows metabolites 
to rotate freely. Due to serum and plasma containing high water concentrations (>50 
M) compared to the rest of the molecules (µM to mM) (141), the water signal must 
be suppressed. This is done by irradiating the water resonance, so that the water 
proton signal vanishes (a process called saturation). Once the water is saturated, 
other signals are more visible.  
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Serum and plasma spectra contain both small and large metabolites. Depending on 
their size, metabolites tumble in solution at different speeds. This influences their 
relaxation rates and in further consequences, the width of their NMR resonances. 
Larger metabolites such as proteins, lipoproteins, and fatty acids, have a reduced 
rotational diffusion, and thus, they tumble more slowly, resulting in faster transverse 
relaxation and broader signals. On the other hand, smaller metabolites rotate faster 
and produce sharper and narrower signals. This information can be used to digitally 
‘filter out’ signals of larger molecules from the spectra.(142) The most commonly 
used pulse sequences in blood metabonomics studies are the spin-echo Carr Purcell 
Meiboom and Gill (CPMG) (143) and the ‘diffusion-edited’(144) methods. 
Small metabolites have relatively long relaxation times compared to larger 
metabolites. Thus, the differences in the relaxation times can be used to manipulate 
the information recorded by NMR. Using a short spin echo delay in the standard 1D 
pulse sequence, prior to data acquisition, lets the peak intensities decay 
proportionally to their relaxation times. Hence, this property contributes to the 
attenuation of signals from large molecules. Consequently, the spectrum will contain 
fewer baseline distortions from larger molecules. On the other hand, when larger 
molecules are of interest, a "diffusion filter" can be applied to eliminate the fast-
diffusing molecules.  
Due to signal loss during relaxation delay, the sequences cannot be used for absolute 
quantification, but only for relative metabolite quantification. Figure 4-1 shows how 
the small metabolites are masked by the large molecule background in a standard 1D 
1
H pulse sequence. The small metabolites are visible in the CPMG spectrum, while 
the large molecules are visible in the diffusion-edited spectrum. In this thesis, both 
CPMG and diffusion-edited pulse sequences have been applied.  
Even after the application of these filters, the 1D NMR spectra can still be crowded 
with extensive peak overlap. This can make it difficult to differentiate between 
multiple peaks and to assign the metabolites. Most metabolites contain several 
hydrogen atoms that resonate at different chemical shifts, and since they often 
overlap with other signals, it complicates the assignment process. To simplify 
spectral interpretation a common approach is to spread the overlapping resonances 
into a second dimension (2D).(145) 
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Figure 4-1 
1
H NMR plasma spectra (500 MHz): standard 1D (top), CPMG (T2-
edited) (middle), and diffusion-edited (bottom). Legend: 3, lactate; 5, alanine; 8, 
citrate; 10, creatine; 11, creatinine; 17, glucose; 18, histidine; 23, lipid CH3; 24, 
lipid (CH2); 25, glycoproteins; 26, choline; 27, lipid CH=CH; 28, valine; 29, 
glutamine; 30, tyrosine; 31, lipid CH2CH2CO; 32, lipid CH2CH=CH; 33, lipid 
CH=CHCH2CH=CH; 34, albumin lysyl CH2. After Diaz Sílvia et al. 2011, (146).  
4.3.1.2 Two-dimensional experiments 
Two-dimensional homonuclear 
1
H-
1
H-TOCSY (TOtal Correlation SpectroscopY) 
and heteronuclear 
1
H-
13
C HSQC (Heteronuclear Single-Quantum Correlation) are 
commonly used 2D NMR experiments in metabonomics studies. These approaches 
are mostly used for metabolite identification, since their acquisition time is often 
long (e.g. 24 hours). TOCSY correlates the entire network of coupled protons in a 
metabolite and produces cross peaks between each pair of protons. HSQC correlates 
the 
1
H and 
13
C shifts for each C-H pair in a molecule. (145, 147) 
4.3.1.3 Metabolite identification 
Metabolite assignment is typically done with the help of different databases (e.g. 
The Human Metabolome Database (HMDB) (148), The Madison Metabolomics 
Consortium Database (149), and the BioMagResBank(150)). These databases match 
the experimental chemical shifts (e.g. 
1
H and 
13
C) against those in the spectral 
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database. For this study a list of NMR chemical shifts found in TOCSY and HSQC 
spectra were uploaded to HMDB (http://www.hmdb.ca/). The database matched the 
shifts and provided a list of potential metabolites, with the number of matching 
resonances. Since the confidence level of correct metabolite assignment depends on 
the number of matching resonances (151), few metabolites with resonances in 
overlapping regions were difficult to distinguish, and hence, they are annotated as 
‘unknown’ metabolites. 
4.4. DATA PROCESSING  
Two types of processing exist for NMR spectra; a pre-processing step and a post-
processing step.  
4.4.1. SPECTRA PRE-PROCESSING 
The pre-processing step includes: adding digital data points to the FIDs to enhance 
the resolution (a process called zero-filling); Fourier transformation; correcting the 
phase to produce pure absorption line shapes and to remove offsets in the peak 
shapes; correcting the baseline; and calibrating the spectra to a reference peak. In 
this thesis, the CPMG spectra were calibrated to the methyl peak of lactate (1.33 
ppm) or alanine (1.48 ppm), while the diffusion-edited spectra were calibrated to the 
methyl signal of N-Acetylglycosamine (2.04 ppm). 
4.4.2. SPECTRA POST-PROCESSING 
The post-processing step consists of: further spectra alignment (if needed); binning; 
normalization; exclusion of spectral regions with non-reproducible information; 
centring; and scaling (if necessary). 
4.4.2.1 Spectra alignment  
Even after the addition of deuterated buffer, small pH variations may occur within 
the sample set. Also, random phasing, peak shape, and small baseline distortions 
may lead to minor differences in the chemical shifts, and to inappropriate peaks 
alignment. In addition, small changes in the temperature, differences in the salt 
concentration, and dilution can also cause peaks shifts.(152) These are usually 
corrected by the calibration and binning (or dividing the spectra into small intervals) 
procedures. However, if some regions are still not properly aligned, specific 
alignment algorithms can be applied. In this thesis, after dividing the spectra into 
equal intervals of 0.001 ppm, some peaks were aligned by using the Icoshift (153) 
algorithm implemented in Matlab.  
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4.4.2.2 Normalization 
Normalization is a significant post-processing step that compensates for variations in 
the RF pulse calibration or dilution of samples. Total intensity normalization is the 
most commonly used technique, which scales each spectrum to a constant total 
intensity. During the procedure, the value of each individual bin is divided by the 
sum of all the bins in the spectrum.(154) In this study, CPMG spectra were 
normalized either to the concentration of glucose measured by blood gas analyser, 
the DSA-d6 peak (4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate), or to 
the total intensity, while diffusion-edited spectra were normalized to the total 
intensity.  
4.4.2.3 Centring and scaling 
Following normalization, data is normally centred. Centring focuses the analysis on 
the fluctuating part of the data. For example, the commonly used ‘mean centring’ 
approach converts the metabolic levels to fluctuations around zero instead of around 
the mean of each metabolite, by subtracting the mean value from each metabolite. 
The approach adjusts for differences in the offsets between high and low abundance 
metabolites, and leaves only the variation between samples in the analysis.  
Scaling approaches aim to adjust for the differences between metabolite 
concentrations by dividing each variable by a unique scaling factor. This often 
minimizes the influence of large values and inflates the influence of small values. 
Small values from baseline noise can also be inflated, making the models more 
prone to overfitting. Therefore, choosing the right scaling is crucial for further 
analyses.  
Auto-, pareto-, vast-, range-, and level- scaling are some of the most common 
methods used in metabonomics studies. Auto- scaling (or unit variance scaling) 
divides each variable by its standard deviation. Pareto-scaling divides each variable 
by the square root of its standard deviation, and is thus an intermediate between 
auto- and no-scaling (mean centring). Vast scaling (or variable stability scaling) 
divides each variable by its standard deviation and its coefficient of variation. Range 
scaling divides each variable by the difference between the minimal and the 
maximal concentration. Level scaling divides each variable by its average or median 
concentration.(155) In this thesis all these scaling methods were tried, however, only 
auto- and no-scaling gave the best results in terms of classification and error of 
prediction. For some models, data was additionally logarithmically transformed 
prior to scaling.  
4.5. DATA ANALYSIS  
After processing, the table of NMR integrals is subjected to different statistical tests. 
Since a spectrum of biofluids contains many dimensions (each dimension 
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corresponding to the intensities of individual metabolites), powerful statistical 
analyses are required to simplify the data (156).  
The more simple univariate tests (e.g. Student’s t -test, analysis of variance or 
ANOVA, Wilcoxon, Kruskal–Wallis) focus on finding a few individual metabolites 
that can separate the samples based on class labels (Figure 4-2a). Metabolites with 
insignificant discriminative power are removed, and hence, data dimensionality is 
reduced. The drawback of these tests is that only significant metabolites are taken 
into account, while combinations of statistically less significant metabolites are not 
assessed. Hence, valuable information can be lost.(157) 
 
Figure 4-2 Approaches to analyse metabonomics data: A) Differences in the 
concentration level of single metabolites between two groups (e.g. t-test). B) 
Multivariate approaches like principal component analysis (PCA) and partial least 
square discriminant analysis (PLS-DA) model the relationships between metabolites 
and/or samples to detect group differences. Each data point represents one sample. 
Two samples that are close to each other on the plot are metabolically similar, while 
two samples that are far away from each other are metabolically different. After 
Bartel, Jörg et al., 2013 (158). 
Multivariate analyses are more complex since they are not limited to a few 
metabolites, and aim to capture the overall metabolic information, including the 
correlation or covariance between metabolites. These analyses can identify 
individual metabolites that are insignificant on their own, but when in combination, 
can produce powerful discriminant models.(139, 157) Multivariate models are either 
unsupervised or supervised. Unsupervised methods are based on finding variations 
in the data without prior knowledge about the class labels, while supervised methods 
introduce knowledge about sample membership. Supervised methods are especially 
useful in finding metabolite combinations and biomarker signatures that are 
discriminative between e.g. case and control subjects. This feature is of particular 
interest in multifactorial diseases where several compounds are affected and where a 
single biomarker is not sufficient to detect the condition.(157) By far the most 
common multivariate methods in NMR-based metabonomics studies are: the 
unsupervised principal component analysis (PCA) (Figure 4-2b); the supervised 
partial least squares or projection to latent structures (PLS) regression; and the 
partial least squares discriminant analysis (PLS-DA) (139, 157, 158).  
a) b) 
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4.5.1. PRINCIPAL COMPONENT ANALYSIS 
PCA attempts to explain the largest variation in the data set. Data is transformed into 
two matrices: a scores and a loadings (or variables) matrix. The scores matrix 
contains the positions of the samples in a new, rotated coordinate system, and can be 
visualized in a scores plot. The coordinate axes of a PCA scores plot are called 
principal components (PCs). These components represent the best-fit of each 
spectrum to a series of PCs. The first principal component (PC1) vector describes 
the largest variation in the data. The second principal component (PC2) is 
perpendicular to PC1, and describes the second largest variation in the data, and so 
on.(159) The PCA scores plot summarizes global similarities and differences 
between NMR spectra based on metabolite concentrations, with each spectrum 
being reduced to a single point. Also, PCA scores plot reveals sample outliers, 
trends and possible clusters (Figure 4-2b). The loadings matrix contains the weights 
for the original variables that are used to calculate samples’ positions on the scores 
plot, and are visualized on a loadings plot.(158, 159) The loadings plot shows the 
relative contribution of each NMR bin (or metabolite) to the principal components, 
and hence, they are important in interpreting the data.(139) 
4.5.2. PARTIAL LEAST SQUARE REGRESSION AND DISCRIMINANT 
ANALYSIS 
When the largest variation in the data is not correlated to the classes, supervised 
methods are used.  
PLS regression is a supervised linear mixed model that combines PCA with multiple 
linear regression analysis to predict a set of dependent variables, Y, from the data 
set, X (NMR spectra). The prediction is achieved by searching for a set of 
orthogonal components, or latent vectors (LVs), that perform a simultaneous 
decomposition of X and Y, to obtain components which explain the covariance 
between X and Y. The LVs obtained from X are then used to predict Y.(159, 160)  
When Y is a categorical response (e.g. case-control, time points), the discriminant 
version of PLS is used. The goal of PLS-DA is to predict the class Y, from X, and to 
find variables that maximize class separation. By orthogonalizing the information in 
the scores plot on the first latent vector (LV1), the model can be more easily 
interpreted. This method is called orthogonal PLS-DA (OPLS-DA), and it highlights 
the between-class separation while reducing the within-class separation. The quality 
of the models is assessed by goodness of fit (R
2
) and its validated fit (Q
2
). A good 
model has R
2
> 0.5 and Q
2
> 0.4 (ranges between 0 and 1), and the results can be 
interpreted as the simple linear regression analysis. To overcome the risk of 
overfitting (e.g. incorporating noise into the statistical models, or finding random 
associations), the results must be validated. The validation process can be done by 
introducing a new set of samples to the model and trying to predict them, or by 
leaving a subset of samples out, calculating the model, and then, predicting the left 
out samples. The latter method is called cross-validation (CV).(139) 
POSTOPERATIVE LUNG INJURY- THE PATH FROM INITIATION TO CLINICAL DIAGNOSIS 
32
 
In this PhD study, PCA, PLS, OPLS, PLS-DA, and OPLS-DA were used. PCA was 
used to identify trends in the data, and to identify possible outliers. Since the diurnal 
variation was larger than the metabolite variation corresponding to the progression 
to hypoxaemia, PCA was only used to assess clusters corresponding to the time of 
sample collection. For the PLS (OPLS) modelling, the PaO2/FiO2 values obtained on 
the third day postoperatively were used to find possible metabolite associations. The 
PaO2/FiO2 was chosen since it is known to be an indicator of the severity of lung 
injury (118). For the PLS-DA (OPLS-DA), the Y vector was segmented into two or 
three classes of zeroes and ones (e.g. PaO2/FiO2≥ 40 kPa vs. PaO2/FiO2< 40 kPa for 
unaffected vs. hypoxaemic patients; PaO2/FiO2≥ 40 kPa vs. 40< PaO2/FiO2< 30 kPa 
vs. PaO2/FiO2< 30 kPa for unaffected vs. mildly vs. severely hypoxaemic patients). 
To avoid overfitting, the Venetian-Blinds CV, the Monte-Carlo CV with sample 
resampling, and permutation testing were used. Additional information about these 
procedures is provided in the attached papers and patent application.  
4.5.3.  OTHER STATISTICAL ANALYSES 
Analyses such as correlation analysis (used to determine metabolites associated with 
the PaO2 values); stepwise multi-linear regression analysis (used to define the best 
combination of predictors of PaO2); the parametric t– and analysis of variance 
(ANOVA) tests, and the non-parametric Wilcoxon and Kruskal–Wallis tests (used to 
quantify the differences between the groups); and the receiver operating 
characteristic (ROC) curve (used to describe the sensitivity and specificity of 
identified putative biomarkers) were also applied. ROC curves show the results of 
two-state cases (e.g. unaffected vs. hypoxaemia). The curve is constructed by 
plotting sensitivity versus 1-specificity of a hypothetical decision boundary that 
moves across the total range of the predictive score (0 and 1 corresponding to the 
unaffected and hypoxaemic patients, respectively). Sensitivity is defined as true 
positives/(true positives + false negative), while specificity is defined as the true 
negatives/(true negatives + false positives). True positives represent the number of 
sick patients correctly identified; true negatives - the number of unaffected patients 
correctly identified; false positives - the number of unaffected patients incorrectly 
identified as hypoxaemic patients; and false negatives - the number of sick patients 
incorrectly identified as unaffected. If the area under the ROC curve is 0.5 the 
models cannot discriminate between classes. On the other hand, if the area under the 
ROC curve is 1, there is complete separation between classes, and samples are 
classified with 100% sensitivity (no false negatives) and 100% specificity (no false 
positives).(161) 
All data analysis was performed in the SPSS (IBM
®
 SPSS
®
 Statistics v.21-23) and 
Matlab R2011b software packages.  
4.6. DATA VISUALIZATION  
Due to the vast quantity of data and the complexity of the modelling methodologies, 
data visualization is an important step in interpreting metabonomics studies. In this 
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study, the NMR data was graphically compared by overlapping spectra, and by the 
scores and loadings plots achieved from multivariate analyses. The validation data 
achieved from (O)PLS-DA models were presented using the multivariate ROC 
curve, which has similar principles to the univariate ROC curve.  
For the visualization of metabolites, several plots were used. When the number of 
metabolites represented was large, heat maps and correlation maps were utilized. 
When one, or few, metabolites were represented, scatter plots, histograms, box-
plots, and ROC curves were applied. Finally, the interaction between metabolites 
was shown by visualizing metabolic reactions.  
For metabolic pathway analysis, the Metaboanalyst (162, 163) tool (v. 2.0 and 3.0) 
was used to identify possible connections between metabolites. The list of identified 
metabolites was mapped into the tool and a corresponding table was produced, 
containing possible reactions for each of the individual metabolites. To produce the 
pathways diagram presented in Study I, additional information from the literature 
was needed (The Medical Biochemistry Page ©1996–2016 themedicalbiochemistry-
page.org, and the Biochemical Pathways Atlas of Biochemistry and Molecular 
Biology (164)).  
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CHAPTER 5. RESULTS AND DISCUSSIONS  
The results for this project are generated based on two papers (Study I, II), a 
manuscript (Study III), and a patent application (Study IV), presented in the 
Appendix section. Since Study I and Study III complement each other, they are 
presented together, while Study II is presented separately. 
5.1. STUDY I AND STUDY III  
5.1.1.1 Study I 
Maltesen R.G. et al., Predictive biomarkers and metabolic hallmark of postoperative 
hypoxaemia, 2016, 12, Metabolomics 
Aim of Study  
No study has characterized metabolic phenotypes in patients undergoing CABG 
with the use of CPB, a well-established risk factor for the development of 
postoperative lung injury (27). Hence, the aim of Study I was to identify early 
biomarkers of postoperative lung injury. 
5.1.1.2 Study III 
Maltesen R.G. et al., Metabotyping Patients’ Journey Reveals Early Predisposition 
to Lung Injury after Cardiac Surgery (manuscript) 
Aim of Study  
While several mechanisms were found deranged in patients progressing to 
hypoxaemia already at the first postoperative morning (Study I), there is still need 
for a better understanding of the molecular reasons as to why certain patients 
develop pulmonary dysfunction, while other do not. Hence, the aims of this study 
were (1) to investigate the time course of metabolite events, from the start of 
surgery, to the clinical symptoms of hypoxaemia observed 72 hours postoperatively; 
(2) to investigate whether it was possible to find a characteristic ‘metabolic 
biosignature’ that made certain patients prone to develop hypoxaemia.  
RESULTS AND DISCUSSIONS  
The metabonomics approach was used since it aims to find insights into the actual 
metabolic phenotype of diseases, and the causes of their progression (83). NMR 
spectroscopy combined with complex multivariate statistical data analyses was used 
as the methodological approach, due to its advantages over classical biochemical 
assays: rapid, reproducible (165), and able to measure hundreds metabolites 
simultaneously in a sample (101).  
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Having samples collected at ten different time points from the pre-, intra-, and post-
operative period collected from different places in the body (radial artery, 
pulmonary artery, and left atrium), allowed us to (1) specifically focus on the 
immediate metabolic effects of the surgical procedure, and to determine whether a 
metabolite was produced, consumed, or just transiently passing through the lungs;  
(2) to create a metabolic journal and follow each patient’s journey through surgical 
trauma towards progression to hypoxaemia or recovery.  
The workflow scheme used to answer the aims of both studies is shown in Figure 5-
1. The steps included sample preparation, acquisition, data processing, data analysis, 
and biological interpretation of results.  
 
Figure 5-1 Workflow scheme for Study I and Study III 
Patient characteristics 
The characteristics for patients enrolled in this project are provided in Table 4-1. All 
patients had normal preoperative PaO2; (mean± SD, 11.3± 1.3 kPa). PaO2 decreased 
to 7.9 ± 1.5 kPa at 48 hours and to 7.8 ± 1.4 kPa at 72 hours, respectively (Figure 5-
2). There was no significant difference between the groups in age, body mass index, 
and smoking habits, however, slightly differences were found in gender (p= 0.01) 
and the duration of CABG and ischemia (p< 0.04), but not of CPB (p= 0.23). 
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Figure 5-2 Partial pressure of oxygen (PaO2) measured in arterial blood on fasting 
patients the day before surgery, and the second and third day postoperatively, to 
assess the degree of hypoxaemia. Arterial PaO2 levels showed a 29% decrease on 
the second (48h) (p<0.0001) and a 31% (p<0.0001) decrease 72h postoperatively 
compared to their baseline levels measured the day before surgery (day-1). Based 
on PaO2 values obtained on the third postoperative day, patients were divided into: 
unaffected patients with PaO2≥ 8.4 kPa and hypoxaemic patients with PaO2< 8.4 
kPa. The hypoxaemic group was further subdivided into ‘mild’ hypoxaemic 
(8.4>PaO2≥ 6.3 kPa) and ‘severe’ hypoxaemic patients (PaO2< 6.3 kPa).  
Metabolome changes as a consequence of surgery 
Besides oxygenation, the levels of several plasma metabolites were also found to 
change on the second and third day postoperatively (Figure 5-3a). Decreases in the 
levels of several amino acids and increases in the levels of ketones, fatty acids, and 
lipids were observed. Similar trends were observed in serum samples collected intra- 
and postoperatively the following 20 hours post-CPB (Figure 5-3b).  
Since patients received nutritional support on days two and three, and since plasma 
and serum matrices are biologically different in terms of the levels of some amino 
acids and lipids (166-168), plasma and serum results were analysed separately.  
To systematically analyse metabolome response to surgery, unsupervised PCA was 
generated on plasma (Figure 5-4a) and serum (Figure 5-4b) samples. PCA 
recognized patients according to the time at which their samples have been 
collected, and clustered them accordantly. Both samples collected at 72 and 20 hours 
postoperatively revealed no overlap with baseline samples (the day before surgery 
for plasma, and the pre-CPB for serum samples, respectively), indicating that the 
metabolome was still perturbed at these time points following surgery.  
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Figure 5-3 The metabolite ‘journal’ of patient no. 12. a) Changes observed in 
plasma the second (green) and third postoperative day (red) compared to the day 
before surgery (blue). b) Changes observed in serum collected during and after the 
surgery: after sternotomy, but before cardiopulmonary bypass (pre-CPB, black); 
immediately after weaning from CPB (0h post-CPB, grey); 2 hours post-CPB (2h, 
orange); 4 hours post-CPB (4h, purple); 8 hours post-CPB (8h, light blue);16 hours 
post-CPB (16h, red); and 20 hours post-CPB (20h, blue green). Abbreviation: h, 
hours; a.u., arbitrary units; 3-HBA, 3-hydroxibutyric acid; N-Ac, N-Acetyl; EDTA, 
ethylene diamine tetraacetic acid. 
a) 
b) 
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Figure 5-4 Metabolome changes as a consequence of surgery. (a) Principal 
component analysis (PCA) performed on 144 plasma projected the samples 
according to their similarities on the first principal components (PC1 and PC2). 
Clear separation is observed between the time at which each sample has been 
collected (blue scores: plasma from the preoperative day, ‘Day-1’; green and red 
scores: plasma from day two and tree, respectively). The largest difference between 
samples is observed the second postoperative day. (b) PCA performed on 688 serum 
samples collected from the left atrium and pulmonary artery during the surgery 
(black, pre-CPB; grey, 0h post-CPB) clustered along PC2, while postoperative 
samples migrated from 2h (orange), to 4h (purple), 8h (light blue), 16h (red), and 
20h (blue green) along PC1.  
Patients’ metabolite journals 
At the end of CPB, the levels of glucose, pyruvate, alanine, lactate, citrate, and 
creatine increased, while the levels of phospholipids, free fatty acids (free FA), 
polyunsaturated fatty acids (PUFA), choline-containing compounds, lipoproteins, 
glycerol, ketone metabolites (3-hydroxybutyric acid, acetate, acetoacetic acid), and 
amino acids, including purine metabolites (inosine, hypoxanthine, uric acid, and 
xanthine), nicotinic acid metabolites (trigonelline, tryptophan), tyrosine metabolites 
(tyrosine and L-dopa), branched-chain amino acids (BCAA; valine, leucine, and 
isoleucine), histidine, and methylhistidine decreased (Figure 5-5). Some metabolites 
have reached baseline levels within few hours postoperatively; however, most 
metabolites continued to change even after 72h postoperatively.  
a) b) 
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Figure 5-5 Time-dependent metabolic changes found in Study III. Abbreviations: 
TMAO, trimethylamine-N-oxide; N-Ac-Gal, N-acetyl-galactosamine; N-Ac-Glc, N-
acetylglucosamine; MUFA, mono-unsaturated fatty acids; PUFA, polyunsaturated 
fatty acids; DAG, diacylglycerol; PEP, phosphoenoylpyruvate; 4.60ppm*, 
unassigned peak; DAGPL: diacylglycerophospholipid; GPC: glycerolphosphocho-
line; PC, phosphatidylcholine; SM, sphingomyelin. 
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Insights into the systemic and pulmonary phenotypes 
While the exact origin of the identified metabolites is unknown, their releases or 
disappearances from pulmonary (LA) and systemic (PA) vasculature may reflect 
their potential location.  
In general, metabolites showed similar trends in both LA and PA samples, with 
slight increases in the levels of some metabolites in the LA samples, indicating their 
production in the lungs (Table 5-1). For example, lactate increased by 33% while 
pyruvate by 61% in PA samples at the end of CPB, with higher levels in the LA 
samples, suggesting a more anaerobic environment in the lungs. Additional 
information is provided in Study III. 
Table 5-1 Metabolite changes over time in relation to both left atrium (LA) and 
pulmonary artery (PA) samples. Significance was assessed by two-way ANOVA. A 
p-value <0.05 was considered significant. Se Figure 5-5 for abbreviations.  
 
Percent mean change (%) Significance 
LA Metabolites 0h 2h 4h 8h 20h p-value 
LA PA LA PA LA PA LA PA LA PA LA PA 
↑ Lactate 36 33 5 0 6 2 -1 -4 -7 -11 <0.0001 <0.0001 
↑ Pyruvate 67 61 36 29 38 35 32 28 41 33 <0.0001 <0.0001 
↑ Acetone 5 -1 108 96 139 132 146 134 97 87 <0.0001 <0.0001 
↑ Free FA -29 -30 221 206 266 260 226 219 222 208 <0.0001 <0.0001 
↑ MUFA -25 -25 49 46 77 76 76 75 63 59 <0.0001 <0.0001 
↑ PUFA -27 -27 38 35 60 59 62 61 59 58 <0.0001 <0.0001 
↑ DAG 15 13 6 8 4 6 12 12 19 14 0.001 0.02 
↑ Glycerol 11 10 26 20 34 32 1 -1 -45 -46 <0.0001 <0.0001 
↑ GPC -7 -7 -14 -16 -14 -17 -14 -16 -10 -11 <0.0001 <0.0001 
↑ Lipoprotein -30 -30 30 28 52 52 60 58 64 60 <0.0001 <0.0001 
↑  Cholesterol -32 -35 1 0 20 18 33 30 38 28 <0.0001 <0.0001 
↓ DAGPL -25 -19 -46 -48 -47 -48 -41 -43 -22 -16 <0.0001 <0.0001 
↓ Ascorbate 2 10 -27 -28 -27 -28 -21 -22 -19 -9 <0.0001 <0.0001 
↓ N-Ac-Gal 16 21 15 13 13 18 -22 -23 -61 -56 <0.0001 <0.0001 
↑ Glucuronate 5 6 15 13 9 9 30 26 100 94 <0.0001 <0.0001 
↑ Glycine -3 -4 -7 -11 -12 -13 -20 -21 -30 -33 <0.0001 <0.0001 
↑ Lysine -3 -3 -9 -11 -18 -19 -23 -24 -30 -32 <0.0001 <0.0001 
↑ Proline -3 -3 -10 -11 -18 -18 -22 -23 -24 -26 <0.0001 <0.0001 
↑ Valine -3 -3 -9 -11 -18 -17 -25 -26 -33 -35 <0.0001 <0.0001 
↑ Isoleucine -14 -14 -28 -30 -39 -39 -44 -44 -33 -35 <0.0001 <0.0001 
↑ Leucine -7 -8 -5 -7 -8 -9 -11 -13 -11 -14 0.004 <0.0001 
↑ Trigonelline -15 -17 -32 -38 -45 -46 -50 -53 -49 -63 0.010 0.001 
↑ Adenine 6 12 56 45 51 47 67 67 65 54 <0.0001 <0.0001 
↑ Inosine -14 -18 -27 -25 -28 -29 -24 -25 -24 -30 <0.0001 <0.0001 
↑ Hypoxanthine -13 -12 -6 -4 -9 -7 4 0 12 8 <0.0001 <0.0001 
↑ Xanthine -16 -16 -26 -26 -24 -25 -14 -16 5 3 <0.0001 <0.0001 
↑ Uric acid -6 -8 -13 -17 -13 -16 -2 -6 24 17 <0.0001 <0.0001 
↑ Tyrosine 4 3 -13 -15 -15 -16 -18 -19 -13 -16 <0.0001 <0.0001 
↑ L-Dopa 0 -1 -8 -10 -11 -12 -11 -12 -7 -9 <0.0001 <0.0001 
↑ Fumarate 2 1 -11 -13 -9 -9 7 -1 8 3 0.04 0.21 
↑ Histidine -1 -1 -9 -11 -14 -15 -13 -14 -14 -16 <0.0001 <0.0001 
↑ 3-Metylhistidine     4 4 11 9 6 6 14 15 36 32 <0.0001 <0.0001 
↑ 1- Metylhistidine    -7 -10 -7 -11 -12 -14 -5 -9 6 0 <0.0001 <0.0001 
↑ Uridine 4 3 -5 -7 -9 -9 -14 -15 -23 -28 <0.0001 <0.0001 
↑ Urea 3 1 4 1 5 4 -4 -6 -24 -27 <0.0001 <0.0001 
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Metabolome screening reveals early signs of lung injury  
Since metabolome changed as a consequence of surgery, metabolome’s potential 
diagnostic value for early detection of the progression into hypoxaemia was 
investigated. Hence, by applying metabolite fingerprinting approach, spectra were 
screened for possible signals associations with later PaO2 values. 
Patient’s history  
Since patient’s history prior to the surgery (age, lifestyle, smoking habits, etc.) is an 
important risk factor for the development of postoperative lung injury (6, 26), it was 
investigated whether such information was embedded in the metabolome. 
Interestingly, partial least square (PLS) regression analysis identified few metabolic 
fingerprints that showed weak associations with later outcomes (cross-validated 
correlation, R
2
cv = 0.43, Figure 5-6a). Although the association is weak, these results 
may suggest that the individual metabolome configuration may play a key role in the 
later development of pulmonary dysfunction.  
Surgical procedure  
PLS analysis performed on samples obtained after sternotomy, but before CPB 
showed a 0.71 cross-validated correlation between metabolome and PaO2 values 
(Figure 5-6b), suggesting that the general anaesthesia and sternotomy procedure 
have affected the metabolome, which in turn, showed predisposition to the later 
development of lung dysfunction. The association increased to 0.92 after weaning 
from CPB (Figure 5-6c), indicating that the CPB and cross-clamp itself contributed 
significantly to the later dysfunction. Same high associations were found the 
following 20 hours postoperatively (Figure 5-6d), indicating that the surgical 
procedure itself had triggered the major chain of reactions that elicited the 
progression into hypoxaemia. To the best of our knowledge, this is the first study 
that demonstrates and quantifies the surgical impact on the metabolome ad it links it 
to later pulmonary dysfunction.  
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Figure 5-6 Metabolome screening reveals early predisposition to hypoxaemia. (a) 
PLS regression revealed a weak cross-validated correlation (R
2
=0.432)between 
plasma metabolome measured the day before surgery (Day-1) with arterial partial 
pressure of oxygen (PaO2) values measured 72h postoperatively. Cross-validated 
(CV) was performed using the Venetian-Blinds approach with 5 segments split. (b) 
PLS reveals a 0.71 predicted correlation between serum metabolome measured after 
sternotomy, but before CPB, and PaO2. A Venetian-Blinds CV approach with 10 
segments splits was implemented. (c) PLS reveals a 0.92 predicted correlation 
between serum metabolome immediately after weaning from CPB (0h) and PaO2 
values. Venetian Blinds approach with 10 segments split was performed for 
validation purpose. (d) PLS reveals a 0.97 predicted correlation between serum 
metabolome at 16h post-CPB and PaO2. The model was validated using a Monte-
Carlo validation (explained in Study I, Appendix A). In addition, all models were 
further validated by using 500x permutation testing. Except for model (a), there 
were no other over-fitted models (p<0.004). Green line, the calibrated results; red 
line, the cross-validated results. 
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The metabolic path towards disease progression  
Since the previous results indicated that the CPB procedure itself has contributed to 
the later development of hypoxaemia, and due to a general longer cross-clamp and 
CABG time for hypoxaemic patients (Table 4-1), the possible effects of prolonged 
surgical procedures on human metabolome was further evaluated. 
Relatively strong associations were identified by PLS regression analysis between 
metabolome and the duration of CPB, cross-clamp, and CABG procedures at 0 and 
2 hours post-CPB (Figure 5-7a). The associations decreased with time, indicating a 
normalization of the metabolome after longer surgical stress.  
Several changes were identified to occur during the surgical procedure (Figure 1d 
and Table 2 in Study III, Appendix C). It was found that metabolome shifted 
towards anaerobic metabolism of glucose by switching from net lactate extraction to 
lactate release. In addition, an increased tricarboxylic acid (TCA) cycle activity, a 
fall in ketone extraction, and a dysregulation of fatty acid and lipid metabolisms was 
observed at the end of CPB.  
Pyruvate and alanine levels were found correlating with the duration of cross-clamp 
and CPB (Figure 5-7b). These metabolites were also found to discriminate between 
hypoxaemic and unaffected patients at 0h (Table 5-2), indicating their link between 
surgery and later development of hypoxaemia. Glycine was found correlating with 
the duration of cross-clamp and with the risk of developing hypoxaemia. In fact, its 
levels provided evidence for groups’ discrimination already before surgery (Table 5-
2, Figure 5-8). Ketone metabolites found inversely correlated with the length of 
CPB, were also found to differentiate between later outcomes. Finally, purine 
metabolites found negatively correlated with the length of cross-clamp, were found 
decreased in patients developing hypoxaemia already before surgery (Figure 5-8), 
indicating a general impairment in their syntheses.  
In conclusion, a characteristic metabolite biosignature was identified that made 
patients prone to develop postoperative lung injury (Table 5-2, Figure 5-8). This 
signature consisted of metabolites involved in the purine metabolism, nicotinic acid 
metabolism, methylhistidine metabolism, tyrosine metabolisms, glycine and 
isobutyrylglycine metabolism, glycolysis and TCA cycle, fatty acids and lipid 
metabolisms, and glycoprotein metabolism.  
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Figure 5-7 The effects of prolonged surgical procedure on the human metabolome. 
(a) PLS regression analysis performed on serum spectra from samples collected 
immediately after weaning from CPB (0h) and 2 hours post-CPB showed cross-
validated associations (R
2
) with the duration of cross-clamp (purple), CPB (green) 
and CABG (red). Higher correlations were observed immediately after weaning 
from CPB. All models were cross-validated using the Venetian Blinds approach with 
10 segments. (b) Metabolites found to correlate both with the duration of CPB, 
cross-clamp, and CABG, and the progression into hypoxaemia. Correlation was 
assessed through the Pearson correlation test (red: positive correlation; yellow: no 
significant correlation; blue: negative correlation).  
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Table 5-2 The chronological metabolic events for the progression to postoperative 
lung injury. Annotation: ‘√’, the time point at which a metabolite was found to 
discern between patients; ‘-‘, metabolites not measured in Study I (16h post-CPB). 
Metabolites Day 
 -1 
Pre-
CPB 
CPB 
(0h) 
2h 4h 8h 16h 20h 
Trigonelline √ √ √ √ √ √ - √ 
3-Methylhistidine √ √ √ √ √ √ √ √ 
Glycine √ √ √ √ √ √ √ √ 
Inosine  √ √ √ √ √ - √ 
Tyrosine  √ √ √ √ √  √ 
Dopa  √ √ √ √ √ √ √ 
Isobutyrylglycine  √ √ √ √ √ √ √ 
Malonate  √ √ √ √ √ √ √ 
Monounsaturated fatty acids (MUFA)  √   √ √ √ √ 
Free fatty acids   √  √ √ √    √ 
PUFA   √ √ √ √ √ √ 
Glycerol   √ √     
Lipoproteins   √ √ √ √ √ √ 
Cholesterol   √  √ √ √ √ 
Phosphatidylcholine   √ √ √ √ √  
Choline   √ √ √    
Hypoxanthine   √ √ √ √ √ √ 
Xanthine   √ √ √ √ √ √ 
1-Methylhistidine   √ √     
Uric acid   √ √ √ √ √ √ 
Isoleucine   √ √   √ √ 
Leucine   √  √ √ √ √ 
Glutamate   √ √     
Alanine   √ √ √ √ √ √ 
Pyruvate   √ √ √ √ √ √ 
Citrate   √ √ √ √ √ √ 
N-Ac-Galactosamine   √ √   √ √ 
3-HBA   √  √ √ √  
Acetoacetic acid   √  √ √ √  
Acetate    √ √ √ √ √ 
Acetone    √ √ √ √  √ 
TAG     √ √ √ √ 
N-Ac-Glucosamine      √ √ √ 
 
 
 
 
 
POSTOPERATIVE LUNG INJURY- THE PATH FROM INITIATION TO CLINICAL DIAGNOSIS 
46
 
Figure 5-8 Selected metabolites showing time- and phenotype dependent changes. 
Each metabolite concentration is represented by its mean and 95% confidence 
intervals. 
Before surgery 
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After sternotomy, but before CPB  
 
At the end of CPB 
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Post-CPB 
 
 
Possible metabolic interpretation  
In plasma samples collected on the day before surgery, we found trigonelline, 3-
methylhistidine, and glycine to differentiate unaffected from hypoxaemic patients 
(Figure 5-8). The question of why these metabolites were different at such an early 
time point is difficult to answer. The levels of these metabolites are similar in both 
males and females (169, 170), and hence, the gender imbalance in the study should 
not have influenced patient grouping the day before surgery. Since metabolites 
reflect lifestyle differences, an alternative explanation to this early differentiation 
may be that the overall patients’ health status before surgery was weakened in 
patient developing postoperative pulmonary dysfunction. While this explanation is 
speculative, further studies are needed to confirm these particular results.  
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Trigonelline has previous been linked to oxidative stress, and its supplementation 
has been shown to attenuate oxidative stress (171). Glycine has been reported to 
have multiple protective effects, and to play central roles in: protection against 
shock caused by haemorrhage and ischemia-reperfusion injury; inflammatory cell 
activation; and free radical formation. Moreover, in plasma membranes, glycine has 
been shown to affect regulation of chloride channels (172) and cell volume (173). 
Hence, its changes may reflect a higher need for protection in hypoxaemic patients. 
Finally, 3-methylhistidine, a marker of tissue damage and inflammation (174), was 
found to increase with time in all patients. However, its levels were relatively 
diminished in the hypoxaemic group at all time points, probably indicating that these 
patients experienced impaired synthesis prior to the surgical procedure.  
While inosine, nicotinic acid metabolites, and 3-methylhistidine levels were found to 
be lower, tyrosine, dopa, glycine, and isobutyrylglycine were found to be elevated in 
hypoxaemic patients after sternotomy, but before CPB, suggesting their potential 
roles as early markers of lung injury. In samples taken just after weaning from CPB, 
alanine, pyruvate, citrate, purine metabolites, BCAA, glutamate, taurine, ketones, 
some fatty acids, and cholesterol could differentiate between later outcomes. At 20 
hours, most of these metabolites could still differentiate patients (Figure 5, Study III, 
Appendix C), signifying their key roles in the early progression of lung injury.  
Previous studies conducted on patients diagnosed with ALI/ARDS have shown 
similar changes with respect to TCA cycle metabolites (89, 175), however, several 
studies are needed to confirm the newly-identified metabolites. Ketones and 
cholesterol have previously been related to ischemia-reperfusion injury and to an 
impaired fatty acid oxidation (176), however, they have not yet been linked to the 
development of lung injury after ischemia-reperfusion. Isobutyrylglycine, a marker 
of impaired mitochondrial FA β-oxidation, was significantly increased in patients 
progressing to hypoxaemia already post-sternotomy, indicating derangements in FA 
metabolism.  
Under homeostatic conditions, various antioxidants are capable of alleviating the 
damaging effects of ROS from the system (177), however, under stress, the 
antioxidant barrier is not sufficient to counteract this damage. Sampling at the end of 
CPB revealed lower levels of the antioxidants inosine and hypoxanthine in patients 
developing hypoxaemia, which may indicate an inefficient scavenging ability, 
leading to a continued ROS presence. Interestingly, previous metabonomics work 
conducted by Evans and co-workers on BALF of patients diagnosed with ARDS 
revealed a 41 fold increase in hypoxanthine levels compared to healthy subjects 
(175). Our results may be complementary to their findings. We found a 30% 
decrease in hypoxanthine levels in patients progressing to severe hypoxaemia at the 
end of CPB, which could indicate that the metabolite may diffuse into the lungs in 
the early stages of pulmonary dysfunction, and that it may accumulate in the later 
stages of full blown disease. To verify this hypothesis, other studies involving both 
blood and BALF samples collected at different time points during disease 
progression should be performed.  
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Glycerol was found to differentiate patients at 0 and 2 hours post-CPB. Glycerol 
release has previously been potentially linked to cellular ischemia-reperfusion injury 
and lipolysis (176), however, it has not been linked to progression to lung injury. In 
addition, free FA, phospholipids, and lipoproteins could discriminate between 
hypoxaemic and unaffected patients at 4h postoperatively and later time points. In 
line with these findings, a recently published study conducted by Sheng and 
colleagues (17) has reported that the levels of circulating fatty acids 2 hours after 
CABG were predictors of the development of hypoxaemia (r =-0.367, p< 0.001).  
N-Acetylglucosamine and N-acetylgalactosamine could also differentiate patients in 
at least two simultaneous time points after CPB, indicating their minor, but still 
significant, roles in ongoing processes. N-acetyl glucosamine has previously been 
linked to increased inflammation after cardiac surgery (178) and to stress conditions 
in general (179), but its levels have not yet been linked to hypoxaemia or 
ALI/ARDS. Finally, several metabolites were found to differentiate between later 
outcomes at two different time points (e.g. urea, creatinine, creatine, arginine, 
valine, histidine, uridine, glucose, and lactate). Since their changes did not following 
a time-line trend, but rather a sporadic trend, they were considered to be less 
significant for disease progression.  
Taken together, these findings suggest that patients progressing to hypoxaemia have 
limited metabolic reserves with regard to ATP production; excessive activated 
lipolysis after surgery; and are more prone to produce an exaggerated stress response 
to CABG.  
Although the study may be the largest of its type published to date, sample sizes are 
still relatively small and involve comparisons between multiple groups. Also, since 
the study was performed on consecutive patients undergoing CABG, we could not 
match for sex differences. Therefore, further studies must be undertaken to address 
these limitations. Another important limitation is the lack of samples collected at the 
beginning of anaesthesia and before sternotomy. Under normal conditions organisms 
utilize several metabolites as fuel substrates, including glucose, lactate, amino acids, 
ketones, and FA. Therefore, having arterial samples just before the induction of 
general anaesthesia, at the beginning of anaesthesia, and before sternotomy would 
have provided information about the effects of anaesthesia and sternotomy on the 
human metabolome. Regarding Study I, only data from samples collected on the 
first morning postoperatively were presented, and hence a significant amount of 
information concerning the course of events involved in disease progression could 
not be investigated. Also, after analysing the time series data, a few metabolites 
found to differentiate patients in Study I could not be reproduced in Study III. This 
is due to the fact that some metabolites showed potential discriminative power at 
only one of the investigated time points. In addition, we mostly used serum samples 
for the analyses. Since the coagulation processes take some time, the samples were 
left at ambient temperature before centrifugation. In this period metabolic changes 
may have occurred. However, all samples were treated equally, and hence the 
differences between samples can be expected to reflect the real changes in the 
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patients. Finally, some of the significant metabolites could not be identified because 
their signals were close to the spectral baseline. In the future, this could be overcome 
by applying mass spectrometry-based techniques, which are more sensitive than 
NMR.  
In conclusion, the scope of Studies I and III was to elucidate the paths towards 
progression to postoperative lung injury and to pave the way for future research. The 
results indicated that metabotyping patients’ journeys at the beginning of, or just 
after the end of CPB, may have potential clinical impact for the early diagnosis of 
postoperative lung injury, and for monitoring the effect of therapeutics targeting 
disease progression. In samples taken whilst patients were still undergoing surgery, 
we found a unique metabolic biosignature that clearly discriminated unaffected from 
hypoxaemic patients. Hence, these metabolites may have potential as early 
biomarkers for the diagnosis of hypoxaemia. 
To the best of our knowledge, this is the first metabonomics study demonstrating the 
link between intra- and postoperative time-dependent metabolite changes and the 
later development of postoperative hypoxaemia. If these results can be translated to 
the clinical setting, this would provide doctors and nurses with a diagnostic 
approach that allows for continuous monitoring of the progression and regression of 
postoperative lung injury.  
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5.2. STUDY II  
Rasmussen B.S. et al., Early coagulation activation precedes the development of 
acute lung injury after cardiac surgery; Thrombosis Research Volume 139, March 
2016, Pages 82–84 
Aim of Study  
 
The aim of this small pilot study was to investigate potential changes in the 
coagulant and fibrinolytic activity in cardiac surgical patients at risk of developing 
postoperative lung injury.  
RESULTS AND DISCUSSIONS  
This was a small pilot study including ten patients selected from the whole cohort of 
fifty patients. Five patients presenting low PaO2/FiO2 (all below 27 kPa), and five 
patients with the highest PaO2/FiO2 (all above 40 kPa) were selected. The severe 
hypoxaemic patients were defined as the acute lung injury (‘ALI’) group, while the 
other five patients were defined as the ‘non-ALI’ or unaffected group. Patient 
demographic data is shown in Table 1 (Study II, Appendix C). 
Two markers of coagulation activity, prothrombin fragment 1.2 (F12) and thrombin-
antithrombin complexes (TAT), and two fibrinolytic markers, D-dimer and plasmin-
antiplasmin complex (PAP) were measured and their plasma profiles were followed 
perioperative (after sternotomy and right after weaning from CPB) and during the 
subsequent 20 hours post-CPB (Figure 5-9a-d).  
The coagulation activity was found increased immediately after CPB in patients 
developing severe hypoxaemia, and reached its maximum within the first 2 hours 
postoperatively (Figure 5-9a,b). D-dimer increased immediately after CPB in 
patients developing severe hypoxaemia compared to unaffected patients (Figure 5-9 
c), possibly indicating that more fibrin was formed. However, the fibrinolytic 
activity measured as PAP, was at the same level in both groups (Figure 5-9d), 
probably indicating that the fibrinolytic activity was insufficient to remove the 
increased amount of fibrin in severe hypoxaemia patients. Similar patterns were 
observed in both LA and PA samples; however, a trend towards higher levels of 
TAT, F12, PAP, but not D-dimer was detected in LA, suggesting that the lungs are 
actively releasing these molecules in the pulmonary microvasculature.  
Since these changes are mostly observed to occur mostly during and after weaning 
from CPB, the time of CPB and cross-clamp was correlated to the levels of TAT, 
F12, and D-dimer. A modest correlation between time of CPB or cross clamp and D-
dimer (r= 0.50, p= 0.02 and r= 0.38, p=0.06, respectively), but no significant 
correlations were observed with the other markers. This result may indicate that the 
pro-coagulant response is influenced by the time on CPB and cross-clamp. 
However, since the number of patients was small, several studies are needed to 
confirm these findings.  
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Figure 5-9 A time course comparison of markers of coagulation (a. TAT; b. F12) 
and fibrinolytic activity (c. D-dimer; d. PAP) observed in patients progressing into 
severe hypoxaemia (ALI; n = 5) and unaffected patients (non-ALI; n = 5).  
These results are in accordance with previous findings which have reported 
increased a procoagulant activity and a decreased fibrinolytic activity in BALF 
samples in patients diagnosed with ARDS (180, 181). In comparison, the findings of 
this study took place immediately after CPB and were related to the later 
progression into lung injury, while previous results were based on diagnosed 
patients.  
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The main limitation of this study was the small number of patients used to envisage 
trends of potential changes. Larger studies are needed to elucidate whether the 
procoagulant response found in this study is causal or just an epiphenomenon.  
In conclusion, an imbalance between coagulation and fibrinolytic activity following 
CPB may be part of the complex mechanism leading to development of 
postoperative lung injury, and thus, to hypoxaemia. 
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CHAPTER 6. CONCLUSIONS 
The aim of this PhD study was to investigate whether metabolomic and coagulant 
activity can be used to detect early signs of lung injury after cardiac surgery, and to 
reveal some of the possible mechanisms involved in disease progression. 
NMR-based metabonomics and ELISA kit assays were applied to pre-, intra- and 
postoperative serum and plasma samples, as part of a strategy to analyse the human 
metabolic, coagulant, and fibrinolytic responses to CABG; to find possible 
predictive biomarkers; and to identify deranged mechanisms, which could 
eventually serve as future therapeutic targets.  
It was found that surgical trauma induced complex series of molecular responses, 
probably intended to reobtain body’s homeostasis and to ensure patient’s survival. 
Metabolite fingerprinting provided a global overview of surgical trauma and allowed 
for the prediction of patients progressing into hypoxaemia. Metabolic profiling 
allowed for the identification and quantification of markers of prolonged surgical 
trauma. In addition, a metabolic biosignature that made certain patients prone to 
develop postoperative lung injury has been identified. Activity assays allowed 
detection of a possible imbalance between coagulation and fibrinolytic activity.  
Patients progressing to hypoxaemia were found to have less metabolic fuel, a more 
anaerobic environment, more impaired fatty acid oxidation, more coagulation 
activity, and deficient fibrinolytic activity. These complex derangements not only 
reflect the critical impact of surgery on the human body, but they also reflect the 
biological system’s attempt to restore its homeostasis after traumatic surgery. Also, 
it was found that patients’ histories (life style, smoking habits, prior diseases, etc.) 
may have amplified the response to the surgery, which in turn, played an important 
role in the development of postoperative lung injury. 
During sternotomy and CPB, tissue trauma, air contact with the heart and lungs, 
temperature shifts, blood contact with the artificial CPB circuit, blood dilution, and 
ischemia-reperfusion, amongst other factors, may have caused significant shifts in 
the metabolome and the coagulation activity. In addition, although similar changes 
were observed in the systemic (PA) and pulmonary (LA) environment, a trend 
towards higher molecular levels was found in LA samples, indicating that the lungs 
are actively involved in the progression of hypoxaemia. Moreover, it was found that 
events occurring within the first day postoperatively (e.g. chest tube drainage, blood 
transfusion, and duration of ventilatory support) did not contribute significantly to 
patient classification, since the associations between the postoperative metabolome 
to the later PaO2 values were not markedly different to that observed after weaning 
from CPB.  
As such, this PhD study indicates that surgery is the main triggering factor of the 
progression to lung injury. In addition, the study provides information about the 
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molecular mechanisms preceding disease progression, and offers evidence for early 
markers of the development of hypoxaemia, that could be used for personalized 
surgical optimization. 
Although novel insights have been obtained, there are still several central questions 
that remain unanswered: 
1. How general anaesthesia and sternotomy affect the human metabolome?  
2. How much lung injury is related to cross-clamp, and how much to CPB 
itself?  
3. Are there metabolites that are lost to the oxygenator filters during CPB?  
4. Are these biomarkers reliable?   
To answer these questions and validate the results further research is needed.  
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CHAPTER 7. PERSPECTIVES AND FUTURE 
DIRECTIONS  
Metabolomics is still a relatively new but rapidly growing field. The approach has 
the potential to impact our understanding of the molecular mechanism of complex 
conditions such as postoperative pulmonary dysfunction.  
The application of NMR and MS-based metabonomics to investigate diseases has 
provided better molecular insights into the perturbed mechanisms. However, for 
application in early diagnosis and prognosis, the technology is still in its 
evolutionary stages. This longitudinal study was the first of its kind, predicting the 
development of lung injury after cardiac surgery, and hence, the learning phase of 
identifying metabolic perturbations may not be finished.  
As highlighted throughout this thesis, NMR-based metabonomics offered some 
unique answers to questions about changes in the human metabolome as a 
consequence of surgical trauma. Also, it offered the possibility to predict the 
progression to pulmonary injury while patients were still undergoing surgery (Figure 
7-1). Hence, metabonomics had some advantages over the standard clinical 
approach, which normally detects hypoxaemia at a later time point.  
Many confounding factors exist. Although the possible influence of several 
confounding factors has been investigated  in Study I (e.g. previous diseases, 
smoking hobbits, age, and body mass index), the proper matching of patients with 
respect to gender should be considered in further studies. In addition, the possible 
effects of medication should also be investigated, since such information would 
provide insights into individual responses to therapeutic interventions. Hence, 
further longitudinal studies are needed to confirm and expand these initial findings.   
During this PhD period, increased focused has been placed on applying 
metabonomics to patients suffering from acute and chronic respiratory diseases at 
the Department of Anaesthesia and Intensive Care Medicine, Aalborg University 
Hospital, and several studies are starting to take form. An example of one such study 
involves patients suffering from chronic obstructive pulmonary disease who 
underwent the same type of surgery (ClinicalTrials.gov identifier: NCT01614951). 
This is a blinded study, which aims to validate the identified markers of surgical 
trauma and of the progression into hypoxaemia. Initial results have identified some 
of the same markers of surgical trauma.   
The main advantage of NMR is its reproducibility (Appendix E), while the clear 
advantage of MS is its sensitivity. Therefore, by combining both platforms, more 
advanced and deeper insights into disease progression may be achieved. Hence, MS 
will also be applied to interpret metabolome perturbations in future studies. The 
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combined platform may help us to achieve the ultimate goal in personalized 
medicine: to provide the right medicine to the right patient at the right time.  
 
Figure 7-1 The progression of postoperative lung injury from 'healthy' state, to 
metabolome homeostatic perturbation, to onset of disease, tot todays' diagnosis. 
Is there any future for metabonomics in clinical practice?  
Before metabonomics becomes a widespread clinical reality, there are two main 
problems to be solved. The first is to make metabonomics technically straight-
forward, from both the data acquisition and the processing point of view, so that it 
can be used in the daily routine by non-specialists. The second problem is related to 
population variation. In general, studies have focused on small, controlled 
populations, and after the identification of markers of a disease, few studies have 
validated the results with new blinded studies. Technical problems will probably be 
solved sooner than population variation, because of advances in automation, 
especially in the NMR field, which will soon allow the use of metabonomics 
routinely for screening purposes. In addition, for hospitals that do not have access to 
such techniques, once metabolic biomarkers are found by these platforms, their 
detection may be done using standard analytical methodologies already 
implemented in the clinical laboratory.    
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Abstract  
Cardiac surgery with the use of cardiopulmonary bypass is a major risk factor 
leading to postoperative lung injury. We hypothesized that the surgical procedure 
elicits metabolic activity that can be related to the development of postoperative 
hypoxaemia. Here we charted metabolic activity in fifty consecutive patients 
undergoing cardiac surgery, by analysing nearly 1500 nuclear magnetic resonance 
spectra run on blood samples collected at nine different time points, from the day 
before surgery to the third postoperative day. We integrated global systemic and 
pulmonary metabolic information by analysing samples from the radial artery, 
pulmonary artery, and left atrium. By metabotyping patients’ journeys from before 
surgery to the third postoperative day, when hypoxaemia was observed, we could 
determine the impact of cardiac surgery on the human metabolome, and identify 
some of the triggering mechanisms preceding the progression to lung injury. The 
surgical procedure induced increases of circulating anaerobic metabolites, and 
decreases in choline-containing compounds, fatty acids, ketones, and several amino 
acids, with slight differences between the global and pulmonary metabolite profiles. 
In addition, the duration of surgical trauma impacted the levels of metabolites 
produced or consumed by the lungs. The results indicate that patients progressing to 
hypoxaemia may produce greater metabolic derangements after traumatic stress. 
Hence, we propose that reduced metabolic adaptability, which cannot meet the 
metabolic challenges of the surgical procedure, may lead to pulmonary dysfunction 
and hypoxaemia. 
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1. Introduction  
Cardiovascular disease is society's number one health problem, being the leading 
cause of death in many countries 
1, 2
. Annually worldwide, nearly one million 
patients undergo coronary artery bypass grafting (CABG) surgery with the use of 
cardiopulmonary bypass (CPB)
3
. Even after uncomplicated procedures, some 
patients experience a systemic inflammatory response and ischemia-reperfusion lung 
injury. Lung injury consists of a series of pathophysiological changes, including 
pulmonary edema, decreased lung compliance, disturbance in the ventilation-
perfusion ratio, and increased pulmonary vascular resistance. Finally, in worse 
cases, this leads to severe postoperative hypoxaemia and acute respiratory distress 
syndrome (ARDS).
4-6
  
Since postoperative lung injury extends hospitalization and increases various 
complications, as well as mortality
6, 7
, it is of interest to identify at-risk patients 
early. Determining the progression into hypoxaemia is challenging, as no early 
diagnostic test exists
8
. Early measurements of the partial pressure of arterial oxygen 
(PaO2) - used to assess the degree of lung injury, and thus, of hypoxaemia
9-11
- has 
shown poor predictive value for later outcomes
12
. Because the nadir values of PaO2 
appear on the second to third postoperative day
13, 14
, it is difficult to predict which 
patients will develop lung injury
15
.    
Currently, there is no proven treatment option
7, 16
 and no molecular-driven 
intervention
17-19
 to prevent disease progression. When lung injury is present, 
supportive care and conservative fluid management are essential
19
. Therefore, an 
understanding of the risk factors and molecular mechanisms may help preventing 
hypoxaemia
6
. A patient’s medical history before cardiac surgery (e.g. age, health 
state, and smoking habits)
4, 20, 21
, previous cardiac surgery
22
, the surgical procedure 
itself (general anaesthesia, sternotomy, atelectasis, and the use of CPB)
4, 23-26
, and 
blood transfusion
22, 27
 are well known risk factors of postoperative lung injury. 
Polymorphisms in the pro-inflammatory interleukin-encoding genes of IL-6 and IL-
18 have been shown to predispose patients to CPB-induced ARDS
28, 29
. In addition, 
increased circulating free fatty acids two hours after CABG have been identified as 
being early signs of postoperative hypoxaemia
6
. In line with these findings, we have 
recently shown that it is possible to predict PaO2 measured the third day 
postoperatively from a blood sample collected on the first postoperative morning
30
. 
Using nuclear magnetic resonance (NMR) spectroscopy and multivariate data 
analysis it was possible to predict the degree of hypoxaemia with high accuracy 
(>79% sensitivity, >92% specificity). A pattern of disturbed metabolism was found, 
of which changes in ketones, amino acids, and lipid metabolism were dominant. 
Metabolites were related to the pathogenesis of hypoxaemia: damaged alveolar-
capillary barrier, edema formation, peroxidation, oxidative stress, impaired 
antioxidant defense, and cell damage. 
30
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While these molecular mechanisms are crucial for the early prognostication of at-
risk patients, there is still need for a better understanding of the molecular reasons as 
to why certain patients develop lung injury, while others do not. Hence, the aim of 
this study was to investigate the time course of metabolic events, from the start of 
the operation, to the clinical symptoms of hypoxaemia observed on the third 
postoperative day. Furthermore, since a patient’s history prior to surgery is an 
important risk factor
4, 20, 21
, we wanted to investigate whether it was possible to find 
a certain ‘metabolic biosignature’ that made certain patients prone to develop 
hypoxaemia.  
We have used a metabonomics approach, since it aims to find insights into the actual 
metabolic phenotype (metabotype
31
) of diseases, and the causes of their 
progression
32
. NMR spectroscopy combined with complex multivariate data 
analyses was used as the methodological approach, due to the advantages over 
classical biochemical assays. First, it is a rapid (within a few minutes
31
), 
reproducible, and relatively cheap technique per sample basis
33
. Second, it measures 
multiple metabolites simultaneously, with little or no sample preparation
34
. Finally, 
NMR provides structural and quantitative metabolic information
35
, providing 
evidence for identifying deranged mechanisms
36
. Since we have serial sampling, 
each patient served as its own control. This allowed us to create an individual 
‘metabolite journal’ and to follow each metabolite profile from before surgery to the 
day of diagnosis. 
2. Methods 
2.1. Patient population and sample collection 
Fifty consecutive patients scheduled for CABG with the use of CPB at Aalborg 
University Hospital, Denmark, were included in this study, after obtaining informed 
consent (NCT02475694). Inclusion criteria were adults above 18 years of age and 
on treatment with statins. Exclusion criteria were treatment with steroids or other 
immune suppressor therapies.  
Patients underwent an overnight fast and standardized anaesthetic, surgical and 
perfusion management. Immediately after anaesthesia, a pulmonary artery (PA) 
catheter was inserted, and after sternotomy, a left atrium (LA) catheter. Paired blood 
samples were collected simultaneously at baseline (before CPB), right after weaning 
from CPB (0 hours), and at 2, 4, 8, and 20 hours after weaning from CPB (when the 
catheters were removed). Three patients were unable to provide samples at 20h 
postoperatively since their LA catheters were displaced. A total of 594 blood 
samples were collected and serum was obtained through standard hospital protocols. 
In addition, three patients were unable to provide samples the second and third day 
postoperatively, hence, a total of 144 blood samples were drawn from the radial 
artery the day before surgery, and at 48 and 72 hours after weaning from CPB, and 
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plasma was obtained. Both serum and plasma aliquots were stored at -80
o
C until 
analysis.   
Postoperatively, patients were treated with supplementary oxygen to achieve 
peripheral oxygen saturations above 95%.  The clinical diagnosis of hypoxaemia 
was based on the ratio between PaO2 and the fraction of inspired oxygen 
(PaO2/FiO2), calculated from PaO2 measured in arterial blood samples collected 48 
and 72 hours after weaning from CPB. In order to standardize the measurements, 
arterial blood samples were taken while patients had been spontaneously breathing 
atmospheric air for 10 minutes. 
2.2. Sample preparation 
Before NMR analysis, samples were thawed for 30 min. at 4°C, vortexed, and 
subsequently centrifuged for 5 min at 12100g and 4°C. A total of 400μL of the clear 
supernatant was mixed with 200μL 0.2M phosphate buffer (pH 7.4, 99% 
2
H2O, 
0.3mM DSA-d6 (1,1,2,2,3,3-hexadeutero-4,4-dimethyl-4-silapentane-1-ammonium 
trifluoroacetate)) in a 5mm NMR tube. Mixture pH was 7.4±0.04. During the whole 
process samples were kept on ice. 
2.3. NMR experiments 
Nearly 1500 one-dimensional 
1
H NMR spectra were recorded on a BRUKER AVIII-
600 MHz NMR spectrometer (BrukerBioSpin, Rheinstetten, Germany) equipped 
with a cryogenically cooled, triple-resonance CPP-TCI probe, at a temperature of 
298.1K (25°C). Spectral acquisition was controlled using the TopSpin 3.1 software 
(Bruker BioSpin).  
T2 filtered Carr-Purcell-Meiboom-Gill (CPMG)
37
 experiments with water 
presaturation were acquired with the following parameters: 65536 data points over a 
spectral width of 20 ppm; 256 scans for serum and 128 scans for plasma samples; 32 
dummy scans; a fixed receiver gain (RG) of 203; and a relaxation delay (d1) of 4s, 
during which presaturation of the water resonance was achieved by continuous 
irradiation at γB1/2π=25 Hz. T2 filtering was achieved with a repeating τ-180°-τ 
pulse sandwich with τ=300μs, repeated 256 times for serum samples and 128 times 
for plasma samples for a total of  80 and 40ms, respectively.  
To achieve more in-depth information about sample lipoprofiles, a one-dimensional 
diffusion-edited pulse sequence was used, with the following parameters: 65536 
data points; 30 ppm spectral width; 128 scans; RG= 114; and d1= 4 s, during which, 
presaturation of the water resonance was achieved by continuous irradiation at 
γB1/2π=25 Hz. Diffusion filtering was achieved by inserting a stimulated-echo 
element into the pulse sequence between excitation and detection (BRUKER 
standard pulse program ledbpgppr2s1d). The diffusion time Δ, during which water 
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presaturation was effective, was 120ms, and bipolar sine-shaped gradients of 52.5 
G/cm and 1.5ms length were used (δ=3ms) for diffusion encoding. An Eddy-current 
delay of 5ms before acquisition was used.  
2.4. Data processing  
Spectral processing was carried out in TopSpin 3.1. FIDs were exponentially 
multiplied, corresponding to a line broadening of 0.3 Hz (CPMG) and 1 Hz 
(diffusion-edited), Fourier transformed, phase and baseline corrected, and calibrated 
(to the chemical shift of the methyl signal of L-alanine at 1.48 ppm for CPMG 
spectra, and to the methyl signal of N-acetylglucosamine at 2.04 ppm for diffusion-
edited spectra). Spectra were reduced to buckets of 0.001 ppm width, and the water 
region between 4.65 and 4.95 ppm was excluded, using AMIX software (Analysis of 
MIXtures, v.3.9.10, Bruker BioSpin, Germany).  
Data was then exported to MATLAB R2011b
38
. The binned data was generalized 
log transformed
39
 to enhance small signals in the spectrum, normalized to either the 
DSA-d6 peak intensity (CPMG) or to total intensity (diffusion-edited), and mean 
centred.  
2.5. Multivariate data analysis  
Data analysis was performed in Matlab R2011b and SPSS (IBM
®
 Statistics v.22). 
For multivariate analysis both unsupervised principal component analysis (PCA) 
and supervised partial least-square regression (PLS) and discriminant analysis (PLS-
DA) were applied using the PLS-Toolbox 6.5 (Eigenvector Research, Wenatchee, 
WA). PCA was applied, to find the main source of variation within the data, to 
check population homogeneity, and to identify outliers based on samples’ metabolic 
similarities and dissimilarities. PLS regression was applied to establish early 
metabolome associations with later outcome. NMR data were regressed to PaO2 
values measured 72 hours postoperatively. In order to find spectral regions that 
correlating significantly with later PaO2 values, the reverse interval-PLS (riPLS) 
approach was applied. Regions found to correlate with PaO2 were then used to 
classify patients according to their diagnosis. For each classification model, a 
receiver operating characteristic (ROC) curve, and a sensitivity and specificity were 
obtained. This information was used to evaluate the metabolome’s ability to predict 
later hypoxaemia.  
For supervised modelling, a ten-fold Venetian-Blinds cross-validation (CV) was 
employed. This validation involves: omitting 10 out of 100 samples from model 
development; developing parallel models from the reduced data; predicting the 
omitted samples; and comparing the predicted and actual values to provide an 
estimate of the model’s overall predictive power. For the PLS regression models, the 
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overall predictive power was assessed by the cross-validated root mean square error 
(RMSECV) obtained from predicting PaO2 values. For PLSD-DA, the CV 
sensitivity and specificity values were used. To ensure that no random model 
performed equally well, or better, than the main PLS and PLS-DA models, 
permutation testing was also performed. Here we scrambled the PaO2 values and 
group labels (hypoxaemia/no-hypoxaemia) 500 times and subsequently performed 
multivariate modelling. The ‘true’ optimal PLS and PLS-DA models were then 
compared to the distribution of the permuted models, and significances were 
calculated using Wilcoxon’s sign rank test. A p-value < 0.004 was considered to be 
significant. 
Models were visualized using scores and loadings plots. Each score represents a 
sample, while each loading represents the variation in a specific spectral region. 
Thus, the sum of all loadings determine the molecular signature or metabolic 
‘fingerprints’ of a patient. The orientation of each loadings variable describes the 
up- and down-regulation of the corresponding bucket containing metabolite 
information. Spectral regions contributing to sample clustering were identified and 
quantified. 
2.6. Metabolite identification 
For the identification process, 
1
H shifts and their corresponding 
13
C signals were 
analysed by running several 2D 
1
H-
1
H total correlation spectroscopy (TOCSY) and 
1
H-
13
C heteronuclear single-quantum correlation (HSQC) spectra. These signals 
were matched to The Human Metabolome Database
40
, Bruker Bbiorefcode Database 
(v. 2.7.0), and literature
30, 41, 42
.  
For metabolite quantification, the NMR peaks were integrated by using the line 
shape analysis option in the AMIX Multi Integration tool.  
2.7. Further analysis and data representation  
Metabolites and PaO2 levels are presented as mean ± standard deviation (SD) and 
percent change in tables, and as bar-plots. Percentage changes were calculated by 
the formula: (Y-X)/X*100; where Y represents a sample collected at a time point 
different from its corresponding baseline sample, and X  represents the baseline 
sample (pre-CPB for serum LA and PA samples; the day before surgery for plasma 
samples collected from the radial artery).  
Several comparisons were undertaken on the data. First, we compared serum 
metabolic profiles recorded at six different time points (before CPB, 0, 2, 4, 8, and 
20 h post-CPB) (Figure 1a,b). Second, the metabolic profiles from before, and right 
after weaning from CPB (0h) were compared in both PA and LA samples (Figure 
1c,d and Table 2). Third, the impact of the duration of the surgical procedure on the 
APPENDIX C. STUDY III 
29 
human metabolome was evaluated (Figure 2a-c). Fourth, patients’ metabolic 
journeys, from the day before surgery to the third postoperative day were analysed 
(Figure 3a,b). Finally, the metabolome’s ability to predict hypoxaemia at an early 
stage was assessed (Figure 4a-f), and the metabolites that were associated with the 
development of later lung injury were quantified and graphed (Figure 5a,b). 
Because patients received nutritional support on days two and three, and since 
plasma and serum matrices are biologically different in terms of the levels of several 
amino acid and phospholipid
43-45
, we chose to differentiate between plasma and 
serum results, and to show results as percent changes. Hence, only the significant 
results obtained from plasma samples are presented in the result section (Figure 3a), 
while additional results is presented in the supplementary part. 
Differences between hypoxaemic patients and unaffected patients were evaluated by 
the χ
2
 test for discrete clinical variables, and by the t-test for continuous variables. 
Differences in paired LA and PA intensities of each metabolite, and differences in 
paired samples collected before commencement of CPB and just after weaning from 
CPB (0 hours), were evaluated with the paired t-test or Wilcoxon signed-rank test, 
depending on the fulfilment of the normality assumptions. The interactions between 
time-, disease-, and LA/PA-dependent metabolic changes were determined by 
factorial analysis of variance (ANOVA), with Tukey’s post-hoc test for multiple 
comparisons.  
Tests of correlation were performed by calculating the Pearson correlation 
coefficient (rp). The 2-sided Fisher exact test was used to determine differences in 
frequency distributions. Statistical significance was defined as a p-value ≤ 0.05.  
3. Results 
3.1. Patient characteristics 
Patient characteristics, surgical variables, and the PaO2 levels are given in Table 1. 
Decreased arterial PaO2 levels were observed on the second and third postoperative 
days compared to the day preceding surgery (Supplementary Figure S1). Forthy 
eight percent of patients suffered hypoxaemia on the second, and 64% on the third, 
postoperative day (PaO2/FiO2< 40kPa). Because oxygenation worsened in some 
patients, whilst it improved in others, between the second and third days (rp= 0.49, 
p= 0.0003), we defined patients’ outcome based on the third day’s PaO2 values. 
Eighteen patients did not develop hypoxaemia (‘unaffected’), while thirty-two 
patients experienced hypoxaemia, of which nine suffered severe oxygen 
impairments (PaO2/FiO2≤  30kPa). 
There was no significant difference between the groups in age, body mass index, and 
smoking habits, however, gender was slightly different (p= 0.01). There was no 
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difference in the perioperative fluid balance (1.97± 0.9L, p= 0.50), or medication, 
between groups. No patient received glucose infusion during the surgical procedure. 
The duration of surgery and aortic cross-clamp (ischemia), but not of CPB, was 
different between groups (p< 0.04). 
3.2. Metabotyping the patient journey  
Each patient’s metabolic journey from the surgical procedure through the intensive 
care unit (ICU) was phenotyped. Spectra run on serum collected at six different time 
points, before CPB and through 20h post-CPB, revealed changes in the levels of 
lipids, ketones, and several amino acids (Figure 1a). These changes were 
consistently seen across all patients.  
PCA performed on LA and PA samples, collected at the six time points, showed 
patients clustering according to the time at which samples were collected (Figure 
1b). Samples collected during surgery (pre-CPB, black; 0h post-CPB, grey) 
clustered along the second principal component (PC2); while postoperative samples 
migrated from 2h (orange) to 4h (purple) to 8h (light blue) and to 20h (blue green) 
along PC1, indicating a possible circadian effect on metabolism. While the 20h 
sample scores approached perioperative samples, they did not overlap. By 48h, 
samples were still not co-mapping preoperative values; while by 72h sample scores 
had moved towards baseline values (Supplementary Figure S2), suggesting that the 
metabolome had almost recovered from surgery.    
3.2.1. The surgical procedure affects the metabolome  
To investigate how the surgical procedure influenced the human metabolome, a 
PCA was performed on 200 LA and PA samples collected during surgery (pre- and 
post-CPB at 0h). Samples clustered according to the time of collection (Figure 1c), 
suggesting that CPB induced changes in metabolite levels. Postoperatively, the 
levels of circulating glucose, pyruvate, alanine, lactate, citrate, and creatine 
increased, while the levels of phospholipids, free fatty acids (free FA), 
polyunsaturated fatty acids (PUFA), choline-containing compounds, lipoproteins, 
glycerol, ketones (3-hydroxybutyric acid, acetate, acetoacetic acid), and several 
other amino acids decreased (Figure 1d, Table 2).  
Similar changes were observed in both PA and LA samples, with a few exceptions 
(Table 2). Lactate increased by 33% while pyruvate by 61% in PA samples post-
CPB; in comparison, their levels were more elevated in the LA samples. The purine 
metabolites including inosine, hypoxanthine, uric acid, and xanthine decreased, 
especially in the PA samples, suggesting their release from the lungs. In contrast, 
citrate and N-Ac-glycoprotein fragment levels were more elevated in the PA 
samples, suggesting their consumption by the lungs. The levels of ketones, including 
3-hydroxybutyric acid (3-HBA), acetoacetic acid and acetate, and the branched-
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chain amino acids (BCAA) leucine and isoleucine had similar increases in LA and 
PA samples. Most lipids and fatty acids showed similar decreases in both PA and 
LA, except for diacylglycerophosphocholine (DAGPL), which was lower in LA 
samples, suggesting its utilization by the lungs.  
3.2.2. The effects of prolonged surgical stress  
Since the time on aortic cross-clamp and CABG was slightly different between 
hypoxaemic and unaffected patients, we evaluated how prolonged procedures 
affected the metabolome. PLS regression, analysing samples collected at 0h and 2h 
against the duration of CPB, and CABG showed moderate cross-validated 
coefficient of association (Rcv) (Figure 2b, Supplementary Table S1), suggesting that 
prolonged surgical procedures stressed the metabolome.  
Lactate, pyruvate, and acetate levels positively correlated with the duration of 
ischemia and CPB at 0h, and with the duration of CABG at 2h, suggesting their 
increased production with the length of surgery. Glycine, alanine, and glutamine 
concentrations correlated with the time of CPB and cross-clamp exclusively at 0h. 
Arginine, isoleucine, and 3-methylhistidine negatively correlated with cross-clamp 
and CABG time, indicating their utilization with prolonged surgical stress. 
Acetoacetate and 3-HBA negatively correlated with the duration of CPB and cross-
clamp at 0h, and positively correlated with the duration of CABG at 2h post-CPB. 
The tricarboxylic (TCA) cycle intermediates fumarate and malate, and the purine 
metabolites inversely correlated with the surgical time. Finally, ethanol correlated 
with the duration of CABG, indicating increased antiseptics with prolonged surgical 
time. 
The associations did not persist for more than 2-4 hours post-CPB, suggesting a 
normalization of the metabolome after longer procedures.  
3.2.3. The post-CPB period 
Postoperatively, several metabolites recovered their pre-CPB levels within the first 
two-four hours; however, most metabolites continued changing until 20h. In fact, 
their levels had not returned to baseline at 48h (Figure 3a). Glycolytic and TCA 
cycle metabolites were mostly elevated in the early postoperative period, but 
returned towards baseline levels in the following 20-48h. The levels of purine 
metabolites, nicotinic acid metabolites (trigonelline and tryptophan), tyrosine 
metabolites (tyrosine and L-dopa), histidine, and uridine were low post-CPB, and 
few of them reached their pre-CPB levels within 8-20h. In contrast, adenine, 
phenylalanine, 3-methylhistidine, glucuronate, and N-Acetyl glucosamine (N-Ac-
Glc) were increased postoperatively, and their levels continued to rise, even after 48 
and 72h. BCAA, lysine, arginine, proline, glutamine, glutamate, glycine, taurine, 
and trimethylamine‐N‐oxide (TMAO) levels were reduced even after 72h.  
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Most fatty acid and lipid concentrations decreased immediately after surgery; 
however, steep increases occurred after 2h post-CPB. Free fatty acids (free FA) 
levels decreased by 30% at the end of CPB, and increased to 2-fold pre-CPB levels 
after 2h at the time sedation was changed from inhalation anaesthesia to intravenous 
propofol administration. Increases in their levels were observed even after propofol 
administration was stopped at 4h postoperatively. The same trends were observed 
for polyunsaturated fatty acids (PUFA), di- and triacylglycerol (DAG, TAG), and 
lipoproteins. On the other hand, lipoic acid concentrations decreased continuously 
after CPB, to 70% at 20h post-CPB, and its signals vanished at 48h. Choline-
containing compounds including diacylglycerophospholipid (DAGPL), glycerol-
phosphocholine (GPC), and phosphatidylcholine (PC) were all found to be 
decreased after surgery, even at 72h postoperatively, except for choline and 
sphingomyelin (SM), which were found to be elevated.  
With respect to differences between PA and LA samples, in general there was a 
similar trend in both samples (Figure 3b). While the levels of some metabolites were 
different at baseline (pre-CPB), their levels were similar in the following 4-8h, and 
returned to the baseline differences afterwards. Phenylalanine, nicotinic acid 
metabolites, most purine metabolites, tyrosine metabolites, histidine, 1-methyl-
histidine, uridine, glucuronate, lactate, pyruvate, acetone, cholesterol, and DAG 
were all elevated in LA samples in at least one time point, indicating their release 
from the lungs. Tryptophan, hypoxanthine, ascorbate, and DAGPL were elevated in 
PA samples in at least one time point, indicating their utilization by the lungs.  
3.2.4. Phenotyping patients’ journeys revealed predisposition to lung 
injury 
Due to the vast changes observed, we explored the potential diagnostic value of the 
metabolome for the early detection of hypoxaemia.  
PLS regression analysis carried out to map metabolome onto arterial PaO2 values 
obtained 72h postoperatively showed moderate association (R
2
cv= 0.71) already with 
samples taken after sternotomy but before CPB (Figure 4a, Supplementary Table 
S2). The validity of using the metabolome for accurately distinguishing hypoxaemic 
from unaffected patients was investigated by building and cross-validating a 
discrimination model based on these samples (Figure 4b). PLS-DA revealed 77.8% 
sensitivity and 84.2% specificity towards differentiating later outcomes (Figure 4c). 
Model robustness was assessed by randomly permuting each patient label 500 times 
and performing the modelling. The real model, based on samples collected after 
sternotomy, outperformed the permuted models (p= 0.004), and gave us confidence 
in the results. 
A larger association, sensitivity, and specificity were observed when analysing post-
CPB (0h) samples (Figure 4d-f, Table S2), indicating that the CPB and cross-clamp 
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procedures played significant roles in the development of lung injury. Models 
performed on samples collected at later time points confirmed these results (Table 
S2).  
The metabolites found to differentiate hypoxaemic from unaffected patients are 
summarized in Figure 5a. We divided hypoxaemic patients according to their PaO2 
levels into a mild (8.4>PaO2>6.3 kPa) and a severe group (PaO2≤6.3 kPa) to 
emphasize the level of impairment and the degree of later lung injury. Most 
discriminatory metabolites were involved in purine metabolism, nicotinic acid 
metabolism, methylhistidine metabolism, tyrosine metabolism, glycine and 
isobutyrylglycine metabolism, fatty acid and lipid metabolisms, and N-Acetyl-
glucosamine metabolism (Figure 5b). When analysing samples taken just after 
sternotomy, purine metabolites, nicotinic acid metabolites, and 3-methylhistidine 
levels inversely correlated with later PaO2 measurements; while tyrosine, L-dopa, 
glycine, and isobutyrylglycine levels positively correlated to the degree of 
oxygenation. The patterns within most of these metabolites continued to be different 
between groups, suggesting their potential as early markers of postoperative lung 
injury. Moreover, the levels of glycerol discriminated patients at time points 0 and 
2h, with highest levels in the severe hypoxaemia group. The levels of free fatty 
acids, phospholipids, and lipoproteins discriminated patients at time point 4h, and 
their levels were inversely correlated with PaO2. N-Acetyl glucosamine, pyruvate, 
alanine, glucuronate, histidine, glucose, lactate, creatine, creatinine, urea, arginine, 
valine, and isoleucine also differentiated patients in at least two of the measured 
time points postoperatively.   
4. Discussion 
The aims of this study were to investigate the impact of cardiac surgery on human 
metabolome and to highlight possible mechanisms involved in the progression of 
postoperative lung injury defined by hypoxaemia.  
The design of the study allowed us to specifically focus on the immediate metabolic 
effects of the surgical procedure, and to determine whether a metabolite was 
produced, consumed, or just transiently passing through the lungs. Analyzing 
samples from nine time points (before, during, and after the operation) allowed us to 
create a metabolic journal and follow each patient through recovery from surgical 
trauma or towards progression into lung injury. Since each patient was their own 
control, potential confounding factors arising from different study populations and 
surgical units were minimized.  
There are several significant findings of the present study. Firstly, NMR 
spectroscopy detected immediate and striking changes in the metabolite profiles of 
both PA and LA samples as a consequence of cardiac surgery (Figure 1, Table 2). 
Secondly, prolonged ischemia, and duration of CPB and CABG impacted the 
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metabolome (Figure 2, Supplementary Table S1). Thirdly, postoperatively, the 
metabolome changed as a consequence of its attempt to reestablish homeostasis 
(Figure 3). Fourthly, the intraoperative metabolome indicated a possible 
predisposition to lung injury (Figure 4, Supplementary Table S2), allowing us to 
identify a ‘metabolic biosignature’ (Figure 5) that made certain patients more prone 
to develop hypoxaemia. 
4.1. The intraoperative period 
During the surgical procedure the beating of the heart and the pulmonary ventilation 
was stopped, the lungs were allowed to collapse, and the blood flow through the 
lungs was limited. For this period, CPB took over the functions of the heart and 
lungs, pumping oxygenated blood through the body. Since we collected blood after 
sternotomy, but before CPB, and right after weaning from CPB (0h), it was possible 
to explore the impact of CPB on the human metabolome.  
We observed dramatic and immediate shifts in the metabolome. PCA showed clear 
separation between pre- and post-CPB samples (Figure 1c), indicating a global 
metabolic stress response to the procedure (Figure 1d, Table 2). Because the surgical 
procedure was an important trigger for the later progression of hypoxaemia, we 
focus here on explaining the possible metabolic derangements found during the 
procedure. 
Our findings are consistent with a general reliance on the anaerobic metabolism of 
glucose to generate ATP; a switch from net lactate extraction to lactate release; a 
compromised TCA cycle activity; a fall in ketone extraction; and a dysregulation of 
fatty acid oxidation. Previous smaller studies on surgical ischemia-reperfusion
33, 46, 47
 
have reported similar responses to surgical trauma. In comparison to these studies, 
we have detected a wider range of metabolites, have analysed both the systemic and 
pulmonary responses to CPB, and have linked these changes to the progression to 
lung injury. Hence, this study gives us new insights into the metabolite responses to 
surgery.  
As patients did not receive glucose under the surgery, increased glucose levels could 
be due to decreased cellular uptake, a common signature of surgical trauma
23, 33, 46
. 
During ischemia and hypoxia, intracellular lactate accumulates and pH decreases, 
and hence, to avoid acute cellular swelling and cell death, lactate must be released 
into the circulation
33, 46
. Hence, the increased lactate levels indicate that cells 
experienced a post-CPB ischemic environment, which was more aggravated in the 
pulmonary microcirculation. Simultaneously increased pyruvate levels suggest that 
pyruvate was diverted away from the pyruvate-dehydrogenase reaction towards the 
anaerobic lactate-dehydrogenase reaction, and towards alanine formation. Decreased 
acetate levels in both PA and LA samples indicate that the acetyl-coenzyme A 
derived from fatty acid oxidation and ketone biosynthesis was compromised. We 
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observed a ~17% decrease in the total ketone levels, a ~30% decrease in fatty acids 
and cholesterol levels, and a 30% increase in citrate levels, indicating that the acetyl-
coenzyme A, which was still being produced from the ongoing fatty acid oxidation 
and ketone production, was being used strictly by the TCA cycle. Decreased ketone 
levels
46
 and inhibition of fatty acids
48
 have previously been related to ischemia-
reperfusion, suggesting a deficiency in fatty acid oxidation.  
We observed that glycerol and DAG levels increased, while several phospholipids 
levels decreased after weaning from CPB. A trend towards more released glycerol 
and decreased phospholipids was noticed in the LA samples, suggesting that the 
lungs were actively involved in these processes. Glycerol release has previous been 
linked to ischemia-reperfusion injury
48
. Glycerol is the phosphoglyceride fraction of 
phospholipids and the backbone of DAG, which is stored intracellularly or in the 
interstitial space. Hence, its release may originate from three different paths: the 
degradation of membrane phospholipids, hydrolysis of glycerol-3-phosphate 
produced during anaerobic glycolysis, and/or lipolysis of intracellular DAG. 
Considering these multiple pathways, increases in glycerol and DAG levels are part 
of a process that indicates potential cellular ischemia-reperfusion injury during CPB.  
A previous study performed on ischemic and hypoxic hearts has shown a 50% 
reduction of phosphatidylcholine in the ischemic and a 22% reduction in the hypoxic 
heart
49
. We found a 17% reduction in choline and PC; a 19% reduction of DAGPL 
in PA, and 25% in LA samples; and a 7% reduction in GPC. These findings suggest 
severe impairments in their biosynthesis during CPB.  
At the end of CPB we also found increased levels of N-acetyl glycoproteins, which 
have previous been linked to increased inflammation after cardiac surgery
47
. In 
addition, the levels of several amino acids were deranged at the end of CPB. One of 
the most interest findings was that the levels of all purine metabolites were 
decreased. These metabolites are by-products of adenosine triphosphate (ATP) 
metabolism, and are known to accumulate during ischemia due to reduced oxygen 
and energy supply. To compensate, cells degrade ATP to adenosine, inosine, and 
hypoxanthine. During reperfusion, when oxygen is reintroduced, xanthine oxidase 
converts hypoxanthine to uric acid and produces highly reactive hydrogen peroxides 
and hydroxyl radicals, which can further react with several molecules in the cell, 
including membrane phospholipids and PUFA
25, 50
. In another study, increased 
purine levels were observed during ischemia, and by 10 minutes post-clamping, 
their levels had decreased significantly
51
. We did not sample at multiple time points 
during the ischemic period. However, we observed an inverse correlation between 
purine levels and the duration of cross-clamp (Figure 2c), indicating that shorter 
ischemic periods may increase their levels, but as the time on cross-clamp continues, 
purines may be used in ongoing processes. Apart from purine metabolites, we also 
observed that during prolong surgical procedures more anaerobic glycolytic 
compounds were produced, while arginine, isoleucine, and 3-methylhistidine were 
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consumed. Arginine and isoleucine are essential amino acids involved in numerous 
processes, while 3-methylhistidine is mainly involved in muscle metabolism. Their 
decreases with the duration of ischemia may indicate an increased demand in their 
utilization that exceeded their rate of production. 
4.2. The postoperative period 
Retaining homeostatic metabolism is an energy demanding process involving many 
metabolites
48
. We observed complex changes in the postoperative period. The 
striking picture that emerges is one of profound impairment in the levels of lipids 
and metabolic fuels, likely reflecting a severe deficiency in energy metabolites, 
impaired TCA cycle, unbalanced pyruvate metabolism, and deranged ketone-, 
nicotinamide-, purine-, and hyaluronic acid metabolism (Figure 3a).  
Some metabolites recovered pre-CPB levels by 2-4h postoperatively; however, most 
metabolites continued changing until 20-72h. We noticed that several metabolites 
were elevated in either LA or PA samples during surgery (Figure 3b); however, their 
levels were similar 2-4h postoperatively, and return to previous differences 
afterwards, indicating the start of a possible systemic and pulmonary normalization. 
One of the most interesting trends was the observation of decreased levels of several 
lipids and fatty acids at the end of CPB, and their steep increase following surgery, 
even several hours after propofol administration was stopped. The depletion may be 
explained by a combination of impaired biosynthesis, hemodilution occurring during 
CPB, and possible entrapment by the oxygenator filters; while the steep increases 
postoperatively may partially indicate the effect of propofol, but also possible 
lipolysis and cell membrane damage. In addition, glucuronate, formed by glucose 
oxidation, was increased significantly until 72h. Glucuronate is involved in the 
degradation and elimination of xenobiotics
40
 and in the synthesis of hyaluronic acid, 
along with N-acetyl-glucosamine
52
, which has been found to be involved in 
pulmonary diseases and lung homeostasis
53
. N-acetyl-glucosamine positively 
correlated with glucuronate, and since their levels were slightly elevated in LA 
samples, it may indicate a possible hydrolysis of the hyaluronic acid within the 
lungs. In addition, purine metabolism increased post-CPB, and reached baseline 
levels at 8-20h, suggesting improved aerobic conditions. Finally, several amino 
acids changed in the postoperative period. The increases in certain amino acids 
might reflect impaired protein synthesis and gluconeogenesis, enhanced proteolysis, 
or decomposition of proteins from skeletal muscles, which are all commonly 
observed after surgical trauma
54
. On the other hand, the decreases in certain amino 
acids levels may indicate their consumption as energy metabolites. It is worth 
mentioning that on the second and third postoperative day patients received 
nutritional support, and hence, some of the changes observed may have been 
affected by nutrition. 
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4.3. The metabolome’s link to the development of hypoxaemia 
Metabonomics has previously been applied to patients exposed to major surgery
54-56
, 
and the approach has shown potential in predicting: systemic inflammatory 
responses and multi-organ dysfunction syndromes
54
, graft failure after kidney 
transplant
56
, and drug-toxicity after liver transplantation
55
. As with these studies, we 
showed that metabolome has great potential in predicting the development of 
postoperative lung injury already during the surgical procedure. 
PLS regression analysis performed on samples obtained after sternotomy, but before 
CPB, showed a 0.71 cross-validated association between the metabolome and 
arterial PaO2 values measured 72h postoperatively (Figure 4a). The association 
increased by 0.2 units (R
2
cv= 0.92) when using samples taken after weaning from 
CPB, indicating that the CPB and cross-clamp itself had significantly contributed to 
the development of later hypoxaemia.  
The metabolites found to be affected by prolonged CPB and cross-clamp time were 
analysed for possible association to hypoxaemia. At 0h, pyruvate and alanine levels, 
which correlated with CPB and cross-clamp time, were also found to associate with 
later outcomes (Figure 5), indicating their links with surgical trauma and the 
development of postoperative lung injury. Glycine, found to correlate the duration of 
cross-clamp, had already increased in patients developing hypoxaemia after 
sternotomy. Interestingly, its levels continued to be discriminative of later outcomes 
even at 20h postoperatively, indicating that glycine may be a good biomarker 
candidate of lung injury. The reason for its pre-CPB elevation is still unknown, since 
we did not collect samples after induction of anaesthesia and before sternotomy. 
Therefore, further studies are needed to confirm and explain its elevation. In 
addition, ketone metabolites inversely correlated with the length of CPB and showed 
decreased levels in hypoxaemic patients. Finally, purine metabolites were negatively 
correlated to the length of cross-clamp and decreased in patients developing 
hypoxaemia, indicating impairments in their syntheses.  
Several metabolites were found to be different between the groups, regardless of 
time on bypass. Free FA, MUFA, TAG, PUFA, lipoproteins, and cholesterol had all 
discriminative value after weaning from CPB. In fact, increased circulating free fatty 
acids have recently been reported as possible predictors of hypoxaemia at 2 hours 
after CABG (r =-0.367, p< 0.001)
6
. We also report these changes straight after 
weaning from CPB, however, the changes became more significant 2-4h post-CPB, 
confirming previous findings. N-Ac-glucosamine levels increased postoperatively in 
all patients, and its levels were positively associated with the development of severe 
hypoxaemia after 8h. In addition, the nicotinic acid metabolites significantly 
decreased in hypoxaemic patients. Tyrosine metabolism (tyrosine, L-dopa) was 
decreased in all patients, however, hypoxaemic patients had smaller decreases 
compared to unaffected patients. Tyrosine metabolism has previously been related to 
POSTOPERATIVE LUNG INJURY- THE PATH FROM INITIATION TO CLINICAL DIAGNOSIS 
38
 
ischemia-reperfusion injury and tissue damage
57
, and hence, their relatively elevated 
levels in hypoxaemic patients may indicate more ischemia-reperfusion injury and 
more tissue damage in these patients. Finally, 3-methylhistidine, a marker of 
inflammation
57
, was found increased with time in all patients, however, its levels 
were lower in patients in patients developing hypoxaemia at all time points, 
probably indicating its utilization by the inflammatory cells. 
Taken together, these findings suggest that patients progressing to hypoxaemia have 
a limited metabolic reserve with regard to ATP production, excessive activated 
lipolysis after surgery, and are more prone to produce an exaggerated stress response 
to CABG. These results confirm our previous findings regarding predictive 
biomarkers of lung injury based on samples collected at 16h post-CPB
30
. In addition, 
we found that metabolites involved in purine-, nicotinic acid-, tyrosine-, hyaluronic 
acid- metabolism were deranged at an early stage, and that the development of 
hypoxaemia can be predicted earlier than anticipated.  
4.4. Study limitations 
Several practical limitations must be acknowledged. Although our study is the 
largest of its type published to date, sample sizes are still relatively small and 
involve comparisons between multiple groups. In addition, since the study was 
performed on 50 consecutive patients undergoing CABG, we could not match for 
sex differences; hence, other studies must be performed to address gender 
differences in relation to metabonomics and postoperative lung injury. In addition, 
since we did not have a new set of samples to validate our results, the validation of 
the identified metabolic biosignature for the progression into hypoxaemia requires 
further studies with larger populations.  
Another important limitation is the lack of samples collected before sternotomy. 
Under normal conditions, organisms utilize several metabolites as fuel substrates for 
ongoing processes, including glucose, lactate, amino acids, ketones, and FA; hence, 
having arterial samples just before the induction of anaesthesia and sternotomy 
would provide us with information about how the metabolome reacted to these 
procedures. In addition, we did not have serum samples on the day before, and the 
second and third day postoperatively. Because the levels of metabolites such as 
phospholipids and amino acids are different in serum and plasma, direct comparison 
could not be achieved for some metabolites, and hence, we reported changes over 
time in percentages.  
5. Conclusion 
The present study is an attempt to elucidate the pathways of early progression to 
postoperative lung injury. It was our aim to improve understanding of the 
mechanistic underpinnings of lung injury, and to pave way for future research.  
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To the best of our knowledge, this is the first metabonomics study demonstrating the 
link between intra- and postoperative time-dependent metabolite changes and the 
later development of postoperative hypoxaemia. We found a unique metabolic 
signature that clearly discriminated unaffected from hypoxaemic patients at least 
48h in advance. Also, the results indicate that metabotyping patients’ journeys early, 
during or just after the end of surgery, may have potential impact in the hospitals for 
the early diagnosis of postoperative lung injury, and for the monitoring of 
therapeutics targeting disease progression.  
 
Figures and Tables 
 
Table 1 Clinical and procedural characteristics of the study population. 
*Independent t- and chi-square test were used to calculate the significance between 
groups. Annotations: n, number of subject; SD, standard deviation; BMI, body mass 
index; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary 
bypass; PaO2, partial pressure of oxygen in arterial blood; FiO2, fraction of inspired 
oxygen (21%); Surgery, from skin incision to last suture. 
 All (n= 50) Hypoxaemia 
(n= 32) 
Unaffected   
(n= 18) 
p-value* 
Subject characteristics 
  Age, mean (range), years 65.8 (48-83) 65.3 (48-83) 66.5 (48-81) -  
  Male, n (%) 41 (82) 23 (72) 18 (100) 0.01 
  BMI, mean ± SD, kg/m2 27.5 ± 0.2 27.2 ± 0.2 28.0 ± 0.3 - 
  Diabetes mellitus, n (%) 14 (28) 10 (31) 4 (22) - 
  Smokers(yes/no/unknown)  16/30/4 11/19/2 5/11/2 - 
  COPD, n (%) 7 (14) 4 (13) 3 (17) - 
Surgical procedure, mean ± SD, min 
  Surgery  196 ± 50 207 ± 52 177 ± 38 0.04 
  Time on CPB  64 ± 29 67 ± 33 57 ± 21 0.23 
 Cross clamp  (Ischemia)  33 ± 19 37 ± 21 25 ± 11 0.03 
72 hours post-CPB, mean (range), kPa 
  PaO2  7.8 (10.7-4.9) 6.9 (8.4-4.9)  9.2 (10.7-8.6)   <0.0001 
  PaO2/FiO2  37.0 (51- 23.3) 33.1 (40-23.3)  43.9 (51-41) <0.0001 
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Figure 1
 
Figure 1 Metabotyping patients’ journeys. (a) Representative 
1
H-NMR CPMG 
spectra of serum collected after sternotomy but before cardiopulmonary bypass 
b) 
d)   Day -1 
a) 
c) 
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(CPB), just after weaning from CPB (0 hours), and 2, 4, 8, and 20 hours 
postoperatively. (b) Principal component analysis (PCA) scores plot of 594 serum 
samples collected at six different time points. (c) PCA performed on samples 
collected before and after CPB. (d) The corresponding loadings plot shows 
metabolite composition on PC2. Abbreviations: 1D, one-dimensional; CPMG, Carr-
Purcell-Meiboom-Gill; 3-HBA, 3-hyroxybutyric acid; FA, fatty acids; PUFA, 
polyunsaturated fatty acids; PaO2, partial pressure of oxygen; kPa, kilopascal; 
ppm, parts per million; a.u., arbitrary units. 
Table 2 
Table 2 Metabolite changes as a consequence of CPB. Metabolite levels found in 
pulmonary artery (PA) and left atrial (LA) samples collected before and after 
cardiopulmonary bypass (CPB). Mean change in percent was calculated using the 
formula: (postCPB - preCPB) / preCPB)*100. Abbreviations: MUFA: mono-
unsaturated fatty acids, DAG: diacylglycerol; PEP: Phosphoenolpyruvate; N-Ac-
Gal: N-acetyl‐galactosamine; DAGPL: diacylglycerophosphocholine; PC: 
Phosphatidylcholine; GPC: Glycerophosphocholine; SM: Sphingomyelin; 
4.60ppm*: unassigned metabolite; 3-HBA: 3-hyroxybutyric acid. 
Metabolites Pre-CPB Post-CPB 
PA (μmol/L) LA (μmol/L) PA  LA  
Mean ± SD Mean ± SD Change 
% 
p-val Change
%  
p-val 
Metabolome 648.3 92.5 640.6 91.7 8 0.01 8.1 0.01 
Inosine 10.2 2.5 10.1 2.6 -18 0.000 -14.4 0.003 
Hypoxanthine 13.9 1.6 13.7 1.9 -21.1 0.000 -20.3 0.000 
Tryptophan 140.4 27.6 140.2 26.8 -22.2 0.000 -24.7 0.000 
1-Metylhistidine 80.8 13.1 79 14.2 -10.1 0.001 -7.4 0.03 
Uric acid 50 9.1 49.1 8.5 -7.9 0.03 -6.2 0.08 
Xanthine 96.6 12.6 95.8 12.9 -16.2 0.000 -15.7 0.000 
MUFA 786.3 213.3 771.9 202.2 -25.1 0.000 -24.5 0.000 
DAG 43.6 8.8 44.5 10.4 12.7 0.003 14.6 0.003 
PEP 174.5 54.1 174.2 50.1 7.5  - 10.3 0.060 
N-Ac-Gal 209.8 85.3 205.9 98.8 21.3 0.02 15.8 0.10 
β-Glucose 5043.2    1616    5015 1554.1 39.5 0.000 38 0.000 
4.60ppm* 141.9 42.6 134.7 37.8 -24.9 0.000 -27.2 0.000 
DAGPL 222.3 48.9 217.3 47.5 -19.1 0.000 -25 0.000 
PC 531.8 73.9 520.4 75.3 -16.6 0.000 -17.7 0.000 
GPC 137.4 15.6 134.9 15.8 -7.1 0.001 -7.4 0.001 
Lactate 1495.3 585.7 1466.7 557.7 32.8 0.000 35.8 0.000 
Glycerol 4870  1820 4763.5 1801 10 0.08 11.3 0.06 
α-Glucose      2144.8 643 2127.3 619.9 35.9 0.000 36.1 0.000 
Choline, SM 793.4 140.3 788.6 132.9 -17.5 0.000 -17.4 0.000 
Creatine 104.5 15.8 105.8 16.3 32.8 0.000 31.4 0.000 
PUFA 543.5 145.3 535.5 140.1 -26.8 0.000 -26.7 0.000 
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Citrate 101.7 13.9 100.9 12.9 30.2 0.000 27.8 0.000 
Pyruvate 43.6 16.7 41.9 16.5 61.3 0.000 67.3 0.000 
3-HBA 168.3 45.9 167.1 45.7 -17.4 0.001 -17.2 0.001 
Acetoacetate 120 50.4 120 50.8 -22.6 0.004 -23.1 0.003 
Acetate 100.3 42.5 98.9 36.8 -19.9 0.060 -18 0.080 
Lysine 489.2 45.9 484.8 47.5 -3.3 0.10 -3.2 0.12 
Arginine 337.4 38.1 334.5 38.4 -6.1 0.009 -5.9 0.010 
Free FA 515.2 199.4 494.9 175.8 -30.2 0.000 -29.4 0.000 
Alanine 482.8 92.9 475.7 88.8 15.1 0.000 15.8 0.000 
Ethanol 492.1 199.3 490.8 223.4 -46.3 0.000 -45.2 0.000 
Isobutyrate & 
Carnitine 
32.1 4.7 31.6 5.2 -7.4 0.01 -6.8 0.03 
Isoleucine 116.8 17.3 116.2 18.4 -14.4 0.000 -14.2 0.000 
Leucine 275.3 37 272.5 38.2 -7.5 0.008 -6.9 0.020 
Lipoproteins 3575.7 852.6 3512.4 812.3 -30.4 0.000 -30.2 0.000 
Cholesterol 50.6 12.4 50.2 11 -34.5 0.000 -32.2 0.000 
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Figure 2  
Figure 2 The impact of prolonged surgical time on the metabolome. Partial least 
square (PLS) regression analysis performed on serum NMR spectra from samples 
collected (a) immediately after weaning from CPB and (b) 2 hours post-CPB 
showed cross-validated (CV) associations with the actual duration of CPB and 
CABG, respectively. Both the calibrated (Cal) and cross-validated (CV) coefficients 
of associations (R
2
) are provided. (c) Metabolites found to correlate with the 
duration of CPB, cross-clamp, and CABG, and their time-line trends until 2 hours 
post-CPB (red: positive correlation; yellow: no significant correlation; blue: 
negative correlation). 
 
 
 
 
 
 
a) 
c) 
b) 
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Figure 3 
  
 
 
  
Figure 3 Patients’ metabolic journeys. (a) Heat map representation of time-
dependent metabolic changes occurring within the nine different time points (the 
day before surgery, ‘Day-1‘; before cardiopulmonary bypass, ’pre-CPB’, 
immediately after weaning from CPB ‘0h’, and 2, 4, 8, 20, 48, and 72h post-CPB. 
(b) Selected metabolites showing similar and slightly different trends in the samples 
collected from the left atrium (LA) and pulmonary artery (PA). Means and standard 
deviations are provided. Abbreviations: 1, 3-MetHis., 1- and 3- methylhistidine; 
TMAO, trimethylamine-N-oxide; N-Ac-Gal, N-acetylgalactosamine; N-Ac-Glc, N-
a) 
b)   Day -1 
Similar trends in LA and PA 
Slightly different trends in LA or PA  
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acetylglucosamine; FA, fatty acids; MUFA, mono-unsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; DAG, diacylglycerol; PEP, phosphoenolpyruvate; 
4.60ppm*, unassigned metabolite; DAGPL, diacylglycerophosphocholine; PC, 
phosphatidylcholine; GPC, glycerophosphocholine; SM, sphingomyelin;  
Figure 4 
Figure 4 Early predispositions to lung injury defined by hypoxaemia. (a) PLS 
regression plot shows cross-validated association between the metabolome 
measured after sternotomy, but before CPB, with arterial PaO2 values measured 
72h postoperatively. (b) PLS-DA prediction scores plot of the cross-validated model 
discriminating patients who will subsequently develop hypoxaemia (black) from 
patients who will not be affected by hypoxaemia (white), from serum samples taken 
after sternotomy, but before CPB. (c) The corresponding receiver operating 
characteristic (ROC) curve showing the predictive capacity of the model with both 
calibrated (Cal, black line) and validated (CV, grey line) results for samples 
collected after sternotomy. (d) PLS regression plot shows cross-validated 
correlation between the metabolome measured after weaning from CPB with PaO2 
values. (e) PLS-DA prediction scores plot of the model discriminating hypoxaemia 
(black) from unaffected patients (white) from serum samples taken immediately after 
weaning from CPB. (f) The corresponding ROC curve. 
a) 
 
d) 
 
b) 
 
c) 
 
e) 
 
f) 
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Figure 5 
 
a) 
 
b) 
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Figure 5 Metabolic signature of lung injury. (a) Heat map representation of the 
mean percent changes in the unaffected (‘None’), mildly affected (‘Mild), and 
severely affected (‘Severe’) by hypoxaemia patients. (b)  Selected metabolites 
showing time- and phenotype dependent changes. Abbreviations: 1, 3-MetHis., 1- 
and 3-methylhistidine; TMAO, trimethylamine-N-oxide; N-Ac-Gal, N-
acetylgalactosamine; N-Ac-Glc, N-acetylglucosamine; FA, fatty acids; MUFA, 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; DAG, 
diacylglycerol; PEP, phospho-enolpyruvate; 4.60ppm*, unassigned metabolite; 
DAGPL, diacylglycerophospho-choline; PC, phosphatidylcholine; GPC, 
glycerophosphocholine; SM, sphingo-myelin;  
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Supplementary materials 
Figure S1 
 
Figure S1 Partial pressure of oxygen (PaO2) measured in arterial blood on fasting 
patients the day before surgery, and the second and third day postoperatively, to 
assess the degree of hypoxaemia. Arterial PaO2 levels showed a 29% decrease on 
the second (48h) (p<0.0001) and a 31% (p<0.0001) decrease 72h postoperatively 
compared to their baseline levels measured the day before surgery (day-1). Based 
on PaO2 values obtained on the third postoperative day, patients were divided in to 
hypoxaemic patients (‘severe’ with PaO2< 6.3 kPa, and ‘mild’ with 8.4>PaO2≥ 6.3 
kPa) and unaffected patients with PaO2≥ 8.4 kPa.        
Table S1        
Table S1 Prolonged surgical procedure affects the metabolome. Association 
between metabolome and duration of surgical procedure assessed by partial least 
square (PLS) regression. Both the calibrated (Cal) and cross-validated (CV) results 
are provided. At 4h post-CPB the association was weaker, suggesting that the 
metabolome had begun normalizing after prolonged surgical stress. No significant 
CV association was observed at 8 and 20h postoperatively. Models with low 
predicted association are marked in grey. 
PLS regression: Metabolome versus duration of surgical procedure 
  
CABG (196 ± 50 min.) CPB (64 ± 29 min.) Ischemia (33±19 min.) 
R
2 
Cal R
2 
CV R
2 
Cal R
2 
CV R
2 
Cal R
2 
CV 
0 hours  - - 0.94 0.76 0.92 0.75 
 2 hours  0.9 0.75 0.87 0.67 0.72 0.54 
 4 hours  0.82 0.6 0.7 0.41 0.7 0.44 
 8 hours  0.68 0.44 0.7 0.36 0.61 0.41 
20 hours  0.74 0.39 0.55 0.32 0.63 0.38 
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Figure S2 
 
Figure S2 Plasma metabolic profiles the day before surgery, and two and three 
days postoperatively. (a) Metabolite profiles of a patient’s plasma samples collected 
the day before surgery (blue), the second (green) and third day (red) 
postoperatively. (b) Principal component analysis (PCA) conducted on CPMG (left) 
and diffusion-edited (right) spectra reveals clear separation between the time at 
which each sample has been collected (white dots: plasma form the preoperative 
day;  grey and black dots represents plasma from days two and three, respectively. 
 
 
 
 
a)   Day -1 
a)   Day -1 
b)   Day -1 
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Table S2 Early prediction of hypoxaemia. Partial least squares (PLS) regression 
and partial least squares –discriminant analysis (PLS-DA) results. The results show 
both the calibrated (Cal) and Venetian-Blinds cross-validated (CV) coefficient of 
association (R
2
), specificity, sensitivity, and class error. Each model was built on 
100 samples collected from 50 patients from the left atrium and pulmonary artery at 
one of the mentioned time points. For validation, the Venetian-Blinds cross-
validation with 10 segments was applied. 10 consecutive samples were removed and 
a model was created. Subsequently, the 10 samples were predicted. This procedure 
was repeated until all samples were removed once. Permutation testing was applied 
for each model. A p-value <0.001 was considered significant. 
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Appendix E. Additional results 
 
1. Fitting accuracy assessment  
 
To integrate peaks of interest the multi-integration fitting tool implemented in 
AMIX (v. 3.9.10, Bruker BioSpin) was used. Peaks were integrated using the sum of 
all points in the specific region as the integration mode.  
To find the accuracy of the fitted signals within a compound, two metabolites were 
compared (Figure E1). Glucose was chosen since its concentration levels were 
higher than the averaged metabolic concentrations (~ 5mM), while trigonelline was 
chosen for the opposite reason (~ 10μM).  
 
Figure E1 The fitted peak areas obtained for the doublet signal derived from α- 
glucose at 5.24 ppm were regressed to that of β-glucose at 4.64 ppm (left). Good 
correlation is observed (R
2
 = 0.992). The fitted peak area obtained for the singlet 
signal of trigonelline at 9.11 ppm was compared to that of the multiplex areas at 
8.84 ppm (right). Good correlation (R
2
 = 0.949) is observed, indicating high fitting 
accuracy. 
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2. Reproducibility assessment  
 
The within and between days reproducibility of NMR was assessed (Figure E2).  
 
Figure E2: For the within day reproducibility (left), a blood sample collected from 
patient no. 11 was run twice, within an interval of approximately 12 hours. High 
correlation is observed between spectra (R
2
 = 0.9997), indicating good within-day 
reproducibility. For the between days reproducibility (right), two different serum 
samples collected from patient no. 20 (both from the pulmonary artery, and both 
collected at exactly same time point - 2h post-CPB), were run within an interval of 
several months from each other. Good correlation is observed between spectra (R
2
 
= 0.9994), indicating good between-days reproducibility.   
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